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1. Introduction 
1.1 General introduction and history of PD 
Parkinson’s disease (PD) is generally defined as a chronic progressive 
neurodegenerative disorder neuropathologically characterized by nigrostriatal cell 
loss and presence of intracellular inclusions called Lewy bodies, leading to the four 
clinical cardinal signs tremor, rigidity, bradykinesia, and postural instability.  
The clinical definition of PD is thus similar to the description given by the famous 
physician James Parkinson in his “An essay on a shaking palsy” published in 1817. 
Based on the observation of people in the streets of London and some of his own 
patients, he was the first to describe “involuntary tremulous motion”, a “propensity to 
bend forwards”, and “to pass from a walking to a running pace” as distinctive 
features of the disease.1 Jean-Martin Charcot then, more than half a century later, also 
distinguished the hallmark of rigidity in his teaching lectures at the Salpêtrière 
Hospital and honored James Parkinson’s work by giving the disease his name.2  
Since then PD has been the subject of comprehensive research, reaching a landmark 
in 1953 when cell loss in the substantia nigra was found in patients with 
parkinsonism, and in the 1960s when depletion of the neurotransmitter dopamine 
could be related to the disease.3, 4 Subsequently, a further milestone in the history of 
PD was reached by the discovery that levodopa, a precursor of dopamine that passes 
the blood-brain barrier, improves parkinsonian symptoms.5 Although a wide range of 
differently acting agents has been developed since, levodopa is still considered to be 
the most effective drug therapy in PD.6 
Also surgical intervention has a long tradition in PD, but played a minor role until 
stereotactic surgery with chronic stimulation of specific brainstem and midbrain 
nuclei was developed and became established during the 1990s.7 Surgical treatment 
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of PD is, however, still limited to a rather small subgroup of patients with fluctuating 
motor symptoms or disabling tremor. 
In the last decade, PD has increasingly been recognized as a disorder that not only 
causes typical motor symptoms, but also a wide range of non-motor problems, 
leading to disability and diminishing quality of life in patients and caregivers.8 The 
fact that most of these symptoms do not respond to dopaminergic treatment indicates 
that also other neurotransmitter systems become involved during the course of the 
disease. There is now increasingly more evidence that PD develops from a restricted 
dopamine-deficit disease to a multisystem brain disorder.9 
In 1997, a new area in PD research was obtained when mutations in the gene coding 
for α-synuclein could be linked to familial parkinsonism.10 This led to the pivotal 
discovery that α-synuclein is the major component of Lewy bodies.11 Later on, 
mutations in several gene loci were shown to be related to inherited PD.12 Although 
such aberrant genes have been found only in a rather small number of PD patients, 
these findings confirmed the long-lasting hypothesis that genetic susceptibility does 
play a role in the etiology of the disease. They also gave new insights into the 
molecular pathogenesis of PD in which mitochondrial dysfunction and impairment of 
the ubiquitin-proteasome system seem to be of crucial relevance.13  
Despite the recent advances in the field of PD, evidence-based knowledge about the 
progression of the disease is still limited. Due to a lack of in-vivo biomarkers and the 
current limitations of neuroimaging methods to adequately measure non-
dopaminergic involvement in PD, clinical assessment using established clinical rating 
scales remains the gold standard in charting the course of the disease.14 A drawback 
of many clinical studies is, however, that they are based on short-term investigations 
and selected patient cohorts. Due to the slowly progressive nature and the 
heterogeneity of the disease, prospective longitudinal studies following representative 
patient cohorts over several years are expected to provide the most valid information 
on the progression of PD. 
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Charting the clinical course of PD is important for several reasons: Valid information 
about motor and non-motor decline and associated risk-factors is valuable in 
anticipating the needs of patients and caregivers and in estimating socio-economic 
costs. Furthermore, it is helpful to design and evaluate the results of epidemiological 
and clinical studies and may have implications for the understanding of underlying 
pathological changes. 
In the present thesis, different aspects of clinical disease progression in PD are 
presented, based on results from four prospective longitudinal investigations, all 
using a population-based cohort of patients with PD. 
1.2 Epidemiology of PD 
Besides essential tremor, PD is the most common neurodegenerative movement 
disorder,15 affecting about 100 to 150 people of 100.000 inhabitants in population-
based studies in Western and Northern European countries.16 The estimated 
worldwide prevalence rate is four million people, with the disease found in all ethnic 
groups, but with geographical differences in prevalence. Annual incidence rates of 
PD in population-based studies in European countries and the USA vary somewhat, 
reporting an age-adjusted crude incidence in between 8.6 and 19.0/100.000 
inhabitants.17 Gender distribution is almost equal, although some studies indicate a 
slight male preponderance.17 As it is mainly an illness of later life and most 
frequently seen after the age of 50 years, it is more common in developed countries 
were people live longer. Approximately 1-2% of the population over 65 years suffers 
from PD, increasing to 3% to 5% in people 85 years and older.18 Early onset of the 
disease is, however, possible, with about 4% of the patients developing clinical signs 
of the disease before an age of 50 years.19  
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1.3 Etiology of PD 
The cause of PD is unclear in the very majority of cases. Previously understood as a 
single entity, clinical studies indicate heterogeneity of PD and increasing evidence 
suggests that the disease may represent different conditions terminating in a common 
pathway.20 
Due to aggregation of PD within families and pedigrees, a genetic cause of the 
disease has been hypothesized for several decades. In several epidemiological studies, 
family members of affected patients were shown to have a 3- to 4-fold increased risk 
of developing the disease compared to subjects in the general population or 
controls.21, 22 A breakthrough in the genetics of PD was the discovery of a mutation in 
the α-synuclein gene on the long arm of chromosome 4 in the Contursi-kindred, an 
Italian family with dominantly inherited early-onset parkinsonism.10 The same 
mutation (Ala53Thr) could later be found in several Greek families, and other 
mutations in the same locus, called PARK1, were identified in German, Spanish, and 
American pedigrees.23 
In the following years several gene loci were found to be associated with autosomal-
dominantly24-27 or recessively28-30 inherited parkinsonism (table 1). Most of the so far 
known gene mutations are associated with juvenile or early onset of the disease, and 
some of them become dominated by atypical features during the course of the 
disease.12 The recently identified leucine-rich repeat kinase 2 (LRRK2) mutations in 
the PARK8 locus, however, appear to cause parkinsonism that resembles sporadic PD 
with respect to both clinical and demographical features.31 While other known gene 
mutations in PD have been identified only in a small number of patients with familiar 
parkinsonism, LRRK2 mutations are shown to be more frequent, and prevalent in 
different populations and continents. In a sample of 435 Norwegian patients with 
well-documented PD and 28 of their relatives, 10 subjects (2.2%) had a specific 
(G2019S) LRRK2 mutation. More recent studies indicate that the same mutation 
might account for in between 13% and 41% of PD cases in Ashkenazi Jews and 
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North African Arabs.32, 33 Other LRRK2 mutations were found in 8% of PD cases in a 
Basque population.27 However, these prevalence rates are derived from selected 
patient cohorts. Whether and to which extent LRRK2 or other gene mutations increase 
susceptibility for the disease in the general PD population has to be clarified in future 
studies. 
Table 1. Loci and genes linked to Parkinson’s disease  
Locus Map position Gene Inheritance Age at 
onset 
Pathology 
PARK1 4q21 α-synuclein Dominant 40s LB 
PARK2 6q25 Parkin Recessive 20-40 No LB 
PARK3 2p13 Unknown Dominant 60s LB, P+T 
PARK4 4q21 α-synuclein Dominant 30s LB, V 
PARK5 4p14 UCH-L1 Dominant > 55 Undetermined 
PARK6 1p35-37 PINK1 Recessive 20-40 Undetermined 
PARK7 1p36 DJ-1 Recessive 20-40 Undetermined 
PARK8 12p11.2-q13.1 LRRK2 Dominant 50-70 LB, pleomorphic
PARK10 1p32 Unknown Unclear 50-60 Undetermined 
PARK11 2q34 Unknown Unclear Late Undetermined 
LB: nigral degeneration with Lewy bodies; P+T: plaques and tangles in some           
V: vacuoles in hippocampal neurons 
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However, genetic causes have not been identified in the majority of PD cases. Twin-
studies in which confounding effects are minimized due to similar or identical 
familial environment and genetic factors, demonstrate relatively low concordance 
rates in monozygotic twins, indicating that environmental factors are important in the 
etiology of PD,34 particularly in those with typical age at onset of the disease.35 A 
caveat of this conclusion, however, is the lack of power in twin-studies to reliably 
detect incompletely penetrant genetic mutations.36  
Various conditions have been suggested to increase the risk for developing the 
disease. A meta-analysis on environmental risk factors and PD reported combined 
odds ratios of 1.26 for chronic well-water use, 1.56 for living in rural areas, and 1.85 
for pesticide exposure.37 In the Honolulu Heart program, following 8000 men 
prospectively for thirty years, working on a plantation for more than ten years was 
associated with a relative risk (RR) for PD of 1.7.38 Due to the recognized association 
between manganese toxicity and parkinsonism, welders were thought to be at 
increased risk for PD. However, recently published large cohort studies argue against 
a relationship between welding and PD.39 In several studies investigating life-style 
risk factors for PD, coffee and alcohol drinking was inversely associated with the 
prevalence of the disease.40 Most consistently, however, cigarette smoking was found 
to be less frequent among patients with PD than controls. A recent meta-analysis of 
prospective studies concluded that patients with PD are at about half the risk to ever 
have smoked compared to controls (RR 0.51).41 Analysis of subgroups revealed that, 
compared to never-smokers, the risk for PD was lowest for current smokers (RR 
0.35) and intermediate for past smokers (RR 0.66). In addition, a dose-response 
relationship has been observed in several studies, with those smoking most 
intensively having the lowest risk of PD. However, risk estimates are different in men 
and women. Several case-control studies found an inverse relationship between 
smoking and PD in men, but not in women. Similar observations were made 
regarding the association between coffee consumption and PD. Therefore, a 
modulating effect of estrogen has been hypothesized.42 
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There are several potential biological mechanisms for the reverse relationship 
between smoking and PD. Direct activation of cholinergic nicotinic receptors in 
substantia nigra and striatum protects dopaminergic neurons against toxicity in 
culture.43 Inhibition of monoamine oxidase enzymes by nicotine might enhance 
elimination or suppress the formation of toxins.44, 45 Induction of cytochrome P-450 
enzymes by polycyclic hydrocarbons contained in cigarette smoke has been 
suggested to contribute to detoxification of environmental toxins that might cause 
parkinsonism, such as MPTP.46 Furthermore, nicotine metabolites may be 
cytoprotective and avoid or slow down neurodegenerative processes.47 
However, despite the apparently convincing findings in in-vitro and animal studies, 
there is still a lack of direct evidence of any neuroprotective effect of smoking with 
respect to the development and progression of PD in humans. Therefore, some 
authors suggest that this association might be due to other reasons. For instance, the 
effect of smoking could be only a symptomatic one, without any neuroprotective 
properties. Selective mortality of smokers also has been introduced as a potential 
confounder of the inverse relationship between smoking and PD, but prospective 
studies argue against this hypothesis.48 Alternatively, the lack to develop strong 
smoking habits might be an early symptom of the disease, reflecting a distinct 
premorbid personality of patients with PD, characterized by wariness, introversion, 
compulsiveness, inflexibility, industriousness, and seriousness.49 Compared to 
controls, PD patients score lower on a personal trait called novelty seeking and higher 
on a trait called harm avoidance, which both may be associated with dopaminergic 
function in the caudate.50, 51 Extreme and unusual behaviors including alcoholism are 
significantly more common in control subjects than patients with PD.52 Finally, gene-
environment interactions have been suggested to modify the association between 
smoking and risk for developing PD.53-55 
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1.4 Molecular pathogenesis of PD 
The discovery of mutations in several genes and the increased understanding of 
dysfunction of their aberrantly encoded proteins have provided important and novel 
insights into the molecular pathogenesis of the disease. There is now increasing 
evidence that oxidative stress, mitochondrial dysfunction, and impairment of the 
ubiquitin-proteasome system (UPS) may represent the central molecular pathways 
and events in the pathogenesis of PD. 
However, also prior to the identification of gene mutations in PD both mitochondrial 
dysfunction and oxidative stress were considered to play a role in the pathogenesis of 
the disease. Defects in mitochondrial complex-I of the respiratory chain were 
consistently found in the SN of patients with PD.56 Further evidence of an 
involvement of complex-I in the pathogenesis of PD was provided by the observation 
that MPTP, an inhibitor of complex-I and contaminant of the manufacture of 
synthetic opiates, caused a syndrome resembling PD in drug abusers.57 MPTP is 
characterized by selectivity for dopaminergic neurons and induces intracellular 
inclusions that contain α-synuclein, resembling Lewy bodies. MPTP, which is similar 
to the widely used herbicide paraquat, leads to selective loss of nigrostriatal 
dopaminergic neurons.58 Also rotenone, a common fish poison, induces parkinsonism 
in animals, but in contrast to MPTP and paraquat, via non-selective inhibition of 
complex-I.59 The observation that it still leads to selective degeneration of 
dopaminergic neurons implies a vulnerability of dopaminergic neurons to complex-I 
deficits. 
The physiological function of α-synuclein is widely unclear, although findings from 
mice models suggest that it may be important for synaptic vesicle recycling with 
relevance for dopamine storage and dopamine transmission.60 As fibrillar forms of α-
synuclein are one of the major components found in Lewy bodies, and increased 
levels in fibrillar α-synuclein are thought to be toxic to neurons, it may play a key 
role in the pathogenesis of PD. Mechanisms by which α-synuclein aggregates in PD 
are, however, not fully understood. As mentioned above, mitochondrial complex-I 
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inhibitors and oxidative stress lead to aggregation of α-synuclein. Also proteosomal 
inhibition in-vivo is associated with increased levels of fibrillization of α-synuclein, 
as well as clinical symptoms of PD.61 On the other hand, overexpression of α-
synuclein promotes mitochondrial deficits and increases sensitivity to oxidative stress 
and dopamine-mediated toxicity.62, 63 In addition, recent studies suggest that 
interactions (“cross-seeding”) between α-synuclein and amyloidogenic proteins like 
tau and β-amyloid may promote the fibrillization of both proteins and play a role in 
the pathogenesis of PD.64 Thus, the pathophysiology underlying α-synuclein 
aggregation and toxicity is complex, and the precise mechanisms and particularly 
their temporal order are still unclear. Therefore, we currently do not know whether α-
synuclein aggregation is the underlying cause or the consequence of mitochondrial 
dysfunction. 
Parkin is involved in the UPS as an ubiquitine-ligase, and strong evidence suggests 
that loss of function of parkin is responsible for young-onset PD in affected 
patients.65 Interestingly, inactivation of parkin did not lead to accumulation of 
putative parkin substrates in the UPS, dopaminergic cell loss, or parkinsonian 
symptoms in knoutout mice models, although mild alterations of dopaminergic 
transmission were found.66 In contrast, loss of neurons in the noradrenergic locus 
coeruleus were observed, as well as decreased mitochondrial respiratory capacity and 
age-dependent increase in oxidative damage in substantia nigra.67 These findings 
strongly suggest an involvement of parkin in the regulation of normal mitochondrial 
function. Also mutations in PINK1 and DJ-1, which likewise parkin cause 
recessively inherited forms of parkinsonism, have been linked to mitochondrial 
dysfunction and oxidative stress.12 The mechanisms by which UCH-L1 and LRRK2 
gene mutations are involved in the etiology of PD are currently poorly understood 
and remain to be clarified. 
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1.5 Neurochemistry and neuropathology of PD 
The pathology of PD is complex, and its pathophysiology and pathogenesis are in 
parts not well understood. Although dopamine depletion and cell loss in the 
nigrostriatal tract, together with the presence of Lewy bodies, are the neurochemical 
and neuropathological hallmarks of PD, there is increasing evidence for dysfunction 
also in other areas of the brain and involvement of pathways other than the 
dopaminergic. While the classical motor features mainly relate to dopaminergic 
pathology, other motor symptoms and particularly non-motor problems are likely to 
reflect changes in non-dopaminergic transmitter systems.9 
PD does not become clinically evident before a substantial loss of dopaminergic 
neurons is reached, probably due to compensatory mechanisms both pre- and 
postsynaptically in the nigrostriatal system.68 Based on neuropathological data, a 60% 
to 80% loss of striatal dopaminergic terminals is needed to induce parkinsonian 
symptoms,69, 70 and the rate of nigral degeneration in patients with PD is eight to ten 
times higher than in healthy age-matched controls. Neuroimaging studies indicate a 
progressive degeneration in the striatum of 4% to 13% per year in PD.71, 72 Whether 
the presymptomatic period is long-lasting or begins in rather close temporal relation 
to the clinical onset is uncertain and object of ongoing research.20, 72 
Reduced activity in non-dopaminergic transmitter systems such as the cholinergic, 
noradrenergic, serotoninergic, and glutamatergic, has also been found in patients with 
PD.73 Studies indicate that these changes may be present even at the clinical onset of 
the disease and become more prominent in advanced stages. In line with these 
neurochemical findings, also pathological studies provide evidence of degeneration 
outside the classical pathway of substantia nigra. Lewy bodies and cell loss have been 
found in different areas of the brain, including brainstem nuclei, prefrontal region, 
and cortex.74 More recent findings from two clinicopathological studies indicate that 
pathological changes typical for PD, Lewy bodies and α-synuclein pathology, may 
evolve sequentially, starting in brainstem and spreading to midbrain, mesocortex, and 
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eventually neocortex.75, 76 Based on their findings, Braak and colleagues suggest a 
staging of PD pathology from stage 1 to stage 6, in which clinical symptoms become 
evident at stage 3 (table 2). In this stage, typical pathological changes, Lewy neurites 
and Lewy bodies, have already spread from lower brainstem regions including the 
olfactory tract and vagus nerve to substantia nigra. This would explain why olfactory 
deficits precede the emergence of motor symptoms in a considerable portion of 
patients with PD.77 Although there is no doubt that depleted dopamine and cell loss in 
substantia nigra play a central role in the pathogenesis of PD, these findings also 
question whether the nigrostriatal pathway is primarily affected in PD, or secondary 
to changes in other areas of the brain. 
Table 2. Staging of brain pathology in idiopathic PD according to Braak et al.75, 76 
Stage Pathology  
1 Medulla oblongata Dorsal IX/X motor nucleus and/or 
intermediate reticular zone 
2 Medulla oblongata and 
pontine tegmentum 
Stage 1 plus caudal raphe nuclei, 
gigantocellular reticular nucleus, and 
coeruleus-subcoeruleus complex 
Presymptomatic 
3 Midbrain Stage 2 plus midbrain including 
substantia nigra pars compacta 
4 Basal prosencephalon 
and mesocortex 
Stage 3 plus prosencephalon, temporal 
mesocortex (transentorhinal region) 
and allocortex (CA2-plexus) 
5 Neocortex Stage 4 plus high order sensory 
association areas of the neocortex and 
prefrontal neocortex 
6 Neocortex Stage 5 plus first order sensory 
association areas of the neocortex and 
premotor areas, occasionally mild 
changes in primary sensory areas and 
the primary motor field 
Symptomatic 
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1.6 Cardinal features and presenting symptoms of PD 
Parkinsonism is a clinical diagnosis and defined by the presence of at least two of the 
four motor signs tremor, rigidity, bradykinesia, and postural abnormalities.78 
Parkinsonian tremor is typically present at rest with a frequency of 4 to 6 Hz. It is 
usually asymmetric at disease onset, often affects the upper extremity, but may also 
be seen in the foot, particularly later during disease progression. Involvement of the 
head is atypical at the beginning of the disease and more typical for essential or 
dystonic tremor. Resting tremor is usually lost during sleep, reduced in action, and 
worsened by excitement, anxiety, or apprehension. 
Rigidity is a form of resistance to passive stretch of skeletal muscles. It is 
independent of the speed of motion and may become apparent as a cogwheel-like 
resistance. 
Bradykinesia describes slowness of movements with difficulties in initiating and 
maintaining motions. Patients with PD may also be unable to perform two motor 
tasks simultaneously or carry out sequences of motor tasks. Bradykinesia is 
considered to be one of the most disabling motor symptoms in PD and may become 
clinically apparent as micrographia, hypophonia, impaired finger dexterity, and 
difficulty in rolling over in bed, among others.  
Postural abnormalities in PD are due to rigidity and loss of the righting reflex, 
resulting in characteristical changes in posture and problems with gait and balance. 
Rigidity affects slightly more flexor muscles than extensors, leading to stooped 
posture with flexion in trunk and neck, and reduced concomitant arm swing. The 
typical parkinsonian gait is small stepped, slow, and shuffling. The righting reflex, 
important to restore and maintain the posture when an external force is given 
suddenly to cause a perturbation of the balance, is impaired, resulting in propulsion, 
instability, and frequent falls. 
  
  25
Besides the typical motor signs, other symptoms may be present when the disease 
becomes clinically manifest. Oily skin and seborrhoic face are signs of autonomic 
dysfunction and due to increase in apocrine secretion rich in lipids. Also constipation 
is common in patients diagnosed with PD. The blood pressure tends to be lower, but 
symptomatic orthostatic hypotension is uncommon at disease onset. Frequent 
urination is often seen at onset of PD, but autonomic and atonic bladders are very 
uncommon. A considerable portion of patients reports olfactory dysfunction when 
clinical symptoms become apparent or even before. Although overt dementia is not 
typical in early stages of the disease, subtle cognitive dysfunction might be seen and 
detected by neuropsychological testing. Depressive symptoms may precede the onset 
of clinical symptoms in PD by several years or even decades. A more detailed 
description of the prevalence of motor and non-motor symptoms and their 
progression over time is given in section 1.9 “Disease progression in PD”. 
1.7 Diagnosis and differential diagnosis of PD 
Parkinsonism may be induced by agents that reduce dopamine-levels in the human 
brain, occur post-infectious, be due to vascular disease, or appear as part of other 
neurodegenerative diseases. However, most commonly parkinsonism is caused by PD 
in which, by definition, the clinical diagnosis has to be confirmed by 
neuropathological findings of Lewy bodies and cell loss in the nigrostriatal tract.  
Parkinsonian symptoms may be subtle at the onset of the disease and misdiagnosis is 
therefore not uncommon.79 Use of strict diagnostic criteria has been shown to 
increase the accuracy of clinical diagnosis in parkinsonian syndromes.80 Features that 
clinically may help to distinguish PD from other parkinsonian disorders are 
asymmetry of motor symptoms, tremor at rest, and good response to levodopa 
treatment. Severe autonomic dysfunction, gaze palsy, and gait dysfunction at disease 
onset are uncommon and may indicate atypical parkinsonian disorders like multiple 
system atrophy (MSA) or progressive supranuclear palsy (PSP). A diagnosis of 
dementia with Lewy bodies (DLB) should be considered in patients with 
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parkinsonian features and early development of cognitive impairment, particularly in 
those with fluctuating hallucinations and other clinical signs of visuospatial or 
executive dysfunction. Parkinsonian features are also seen in a considerable portion 
of patients with Alzheimer’s disease (AD). For a more detailed overview see table 3. 
Table 3. Differential diagnosis in parkinsonian disorders 
Type of parkinsonism Subtype/cause 
Parkinson’s diseasea • Idiopathic 
• Familial 
Symptomatic parkinsonism • Drug-induced 
• Neuroleptics, antidepressants, lithium 
• Antiemetics 
• Antihypertensive agents, antiarrhythmics
• Vascular disease 
• Intoxication (MPTP, rotenone, others) 
• Traumatic 
• Post-infectious 
• Neoplasm 
• Normal pressure hydrocephalus 
Parkinsonism due to other 
neurodegenerative disorders 
• Atypical parkinsonism 
• Multiple system atrophy (MSA)a 
• Progressive supranuclear palsy (PSP)b 
• Corticobasal degeneration (CBD)b 
• Dementia with Lewy bodies (DLB)a 
• Alzheimer’s diseaseb 
• Others 
a Synucleinopathy; b Tauopathy 
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1.8 Assessment of disease severity and progression in PD  
1.8.1 Clinical assessment of parkinsonism and disability 
There are several established clinical instruments to measure the severity and 
progression of motor symptoms and disability in PD: 
The most widely used rating tool in PD is the Unified Parkinson’s Disease Rating 
Scale (UPDRS), which was introduced in 1987 by an international group of 
movement disorders specialists.81 The UPDRS was designed to follow the 
longitudinal course of the disease and has been shown to be both reliable and valid. It 
is divided in four parts (subscales), covering symptoms of mentation, behavior, and 
mood in part I, activities of daily living in part II, motor symptoms in part III, and 
complications of therapy in part IV. Each item in part I to III is quantitatively scored 
on a 5-point scale (from 0 to 4). Despite its strengths, the UPDRS is currently under 
revision to adapt it to recent scientific advances, particularly to better capture the 
wide spectre of non-motor problems experienced by patients with PD. 
The Hoehn and Yahr scale82 was devised in 1967 and is the other main scale used in 
PD. It measures the severity of the disease, including both impairment and disability 
of movements, balance, and gait, by allocating stages from 0 (no visible symptoms of 
Parkinson’s disease) to V (parkinsonian symptoms on both sides and not able to 
walk). It has been shown to correlate with neuroimaging studies of dopaminergic loss 
and other clinical scales of motor impairment and disability. Non-motor symptoms 
are, however, not captured by the scale. 
The Schwab and England scale83 assesses the patients’ ability to perform daily 
activities in terms of speed and independence on a range from 0% (bedridden, 
vegetative dysfunction, complete invalid) to 100% (completely independent, 
essentially normal). 
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1.8.2 Clinical assessment of non-motor problems 
1.8.2.1 Assessment of cognitive impairment and dementia 
There are several instruments to assess cognitive impairment and dementia in PD. In 
early stages of the disease, cognitive dysfunction may be subtle and thus not 
assessable by clinical rating tools. Hence, neuropsychological testing is helpful to 
detect early changes in cognitive function in patients with PD. However, it may also 
be useful in more advanced stages of the disease.  
The Mini-Mental State Examination (MMSE)84 is the most widely used and validated 
screening tool of cognitive impairment. It consists of 30 items covering orientation in 
time and space, recent and distant memory, attention, language, and the ability to 
follow simple verbal and written commands. The MMSE provides a total score 
indicating the cognitive function of an individual. 
The Gottfries, Bråne & Steen Dementia Scale (GBS)85 rates severity of dementia and 
provides a profile of the symptoms of dementia by estimating motor, intellectual, 
emotional, and other features characteristic of dementia in four subscales. Each item 
is scored on a clearly defined 7-point scale (0 indicates normal functioning and 6 
indicates maximal severity). The rating is based on observation of the patient and an 
interview of the patient and a caregiver. 
The Dementia Rating Scale (DRS)86 is a commonly used cognitive rating instrument 
designed to assess the course of decline in dementia. It has five subscales measuring 
attention, initiation, construction, conceptualization, and memory. Scores range from 
0 (maximal severity) to 144 (normal cognitive function). The DRS is a valid and 
reliable assessment tool of cognitive functioning in older adults. 
The Diagnostic and Statistical Manual of Mental Disorders (DSM)87 includes 
standardized diagnostic criteria for the diagnosis for several psychiatric disorders. 
The revised third and the fourth edition of the DSM define dementia as follows: 
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“The essential feature of dementia is impairment in short- and long-term memory, 
associated with impairment in abstract thinking, impaired judgement, other 
disturbances of higher cortical function, or personality change. The disturbance is 
severe enough to interfere significantly with work or usual social activities or 
relationships to others. …” 
1.8.2.2 Assessment of fatigue 
Since fatigue is a subjective problem lacking objective correlates, it is most 
appropriately assessed by measuring the patient’s own perception of this complaint 
by self-report. A range of self-completed questionnaires has been developed to 
measure the severity of fatigue for clinical and research purposes. As fatigue in PD 
may overlap with other features such as depression and apathy, these should be 
assessed in parallel. In addition, other medical conditions may be considered as 
potential causes of fatigue. 
The most widely used measurement instrument is the Fatigue Severity Scale (FSS),88  
a nine-item scale assessing the influence of fatigue on activities on daily living. Each 
item is graduated from 1 (strong disagreement) to 7 (strong agreement), and the mean 
score of the nine items is the patient’s score in FSS. Originally developed to measure 
fatigue in patients with multiple sclerosis, the FSS has been shown to be reliable and 
internally consistent. It is brief and easy to administer. 
The Fatigue Assessment Inventory (FAI)89 is an expanded version of the FSS, 
including 29 items. It assesses both quantitative and qualitative aspects of fatigue. 
Although the FAI demonstrates good psychometric qualities, its reliability has been 
characterized as only moderate, with only two of its four factors showing validity 
with other measurements of fatigue.90 
The Fatigue Severity Inventory (FSI)91 was developed for use in patients with PD, 
adapted from the FAI and extended to 33 items. The FSI has shown concurrent 
validity with other measurement instruments of fatigue. 
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The Multidimensional Fatigue Inventory (MFI)92 is a 20-item self-completed 
instrument measuring five dimension of fatigue: general fatigue, physical fatigue, 
mental fatigue, reduced motivation, and reduced activity. Each dimension exists of 
four items which are rated from 1 (no fatigue) to 5 (very fatigued). It is a validated 
and reliable measurement instrument of fatigue. 
Recently, a further measurement instrument of fatigue, designed for patients with PD, 
has been introduced. The Parkinson Fatigue Scale (PFS-16)90 is a 16-item self-report 
instrument designed to assess physical aspects of fatigue and their impact on daily 
functioning. The PFS-16 shows high internal consistency and satisfactory test-retest 
reliability. 
1.8.3 Neuroimaging in PD 
Structural brain imaging using computed tomography of the head (cranial CT) and 
magnetic resonance imaging (MRI) are expected to be normal in uncomplicated PD. 
It is, however, useful to exclude other conditions leading to parkinsonian symptoms, 
such as vascular parkinsonism, and may help to distinguish PD from other 
neurodegenerative syndromes like MSA and PSP. 
Functional brain imaging is increasingly used in diagnostics of PD and for 
assessment of the severity and progression of the disease. Single-photon emission 
computed tomography (SPECT) and positron emission tomography (PET) using 
dopamine-ligands are the currently primary neuroimaging techniques in PD.93 
Reduced striatal dopamine-uptake or metabolism in the striatum, usually 
asymmetrical and more pronounced in the putamen than in the caudate, are typical 
findings in early PD. PET and SPECT are characterized by high sensitivity and 
specificy in distinguishing patients with PD from age-matched healthy controls. 
Studies of β-CIT SPECT with blinded readings reported diagnostic sensitivity of 
greater than 95% and specificity in between 83% and 100% for clinically probable 
PD compared with essential tremor.93 However, none of these neuroimaging 
techniques reliably distinguishes PD from atypical forms of parkinsonism. 
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Both SPECT and PET have increasingly been used in clinical trials to indirectly 
measure disease progression. A number of studies using imaging ligands have 
demonstrated that the reduction in ligand binding correlates with motor severity in 
PD.94-96 This is particularly true for akinesia, axial symptoms, and, to a less extent, 
rigidity.97 Interestingly, several studies found that tremor at rest and action tremor are 
not related to the degree of dopaminergic denervation measured by striatal dopamine 
transporter binding or dopamine metabolism.97 However, recent results from studies 
using imaging endpoints to assess disease progression, as the ELLDOPA trial, 
question the validity of currently applied neuroimaging methods in assessing changes 
in disease severity in PD.98 Low reproducibility due to scan-to-scan variability and 
confounding effects by study medication, leading to downregulation of dopamine 
transporter activity, are currently considered to be the main problems of 
neuroimaging techniques used in PD.99 In addition, measuring dopamine metabolism 
or dopamine transporter activity only appears to be insufficient in reflecting the 
severity or progression of a disease in which a variety of symptoms are due to non-
dopaminergic involvement. More recently, functional imaging using acetylcholine 
esterase (AChE) and choline acetyl transferase (ChAT) radioligands has been 
introduced to assess neurochemical deficits in cholinergic pathways in PD,100 and 
carbon-11 labeled RTI-32 PET was used to study the role of catecholaminergic 
neurotransmission in depression of patients with PD.101 However, these and several 
other tracers are thus far reserved to research purposes. 
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1.9 Disease progression in PD 
1.9.1 Motor symptoms and disability 
Tremor at rest is the most common motor symptom at disease onset, prevalent in 
60% to 70% of patients with PD.102-104 However, 25% of patients with PD never 
develop tremor.103 Bradykinesia and rigidity are less common, but still frequently 
seen at onset of PD. The usually good clinical response of these cardinal features to 
levodopa treatment and their correlation with changes in dopamine transporter 
activity and dopamine metabolism in neuroimaging studies implies underlying 
deficits in the dopaminergic nigrostriatal system. In the very majority of patients, the 
initial motor symptoms are localized to the upper extremities,105 spreading to the 
other ipsilateral limb within one to three years and affecting the contralateral limbs in 
three to eight years.106 The asymmetrical pattern, however, usually persists during the 
course of the disease, even in advanced stages.80  
Axial symptoms, including postural instability and impairment of speech, are not 
typical at disease onset, but become a common complication of advanced PD. In a 
community-based study of 128 patients with PD, 64% had postural instability with 
falls and 49% had speech difficulties at an average of six years of disease duration. 
Only 1% of these patients reported unsteadiness as their initial symptom.107 The 
control of balance and gait is complex, involving brainstem and midbrain locomotor 
areas, and motor cortex.108 However, findings from several studies provide evidence 
that degeneration in cholinergic brainstem nuclei, particularly the pedunculopontine 
nucleus (PPN),108, 109 is crucial for development of postural instability and gait 
problems which both increase the risk of falls and injuries. About 70% of patients 
with PD fall at least once each year.110 
Freezing of gait (FOG) is an important source of falls.111 FOG describes the patients’ 
difficulty to move their feet and may become apparent as start-hesitation or halting 
when walking. FOG often occurs suddenly, may be triggered by visual stimuli like 
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narrow spaces and doors, tends to be transient, and may appear both in on- and off-
state. In the DATATOP trial, 7% of patients with mild PD reported FOG before 
treatment was initiated.112 26% of patients experienced FOG at the end of the study. 
In a long-term study, 42 of 52 patients (81%) had fallen due to the disease.113 FOG is 
strongly associated with the severity of the disease, while the duration of the disease 
per se does not seem to be a major risk factor. The pathophysiological basis of this 
phenomen is poorly understood, but a strong association with development of axial 
symptoms may indicate common underlying pathology.112 
Although the nature of PD is usually described as slowly progressive, only few 
prospective studies have given estimates on the rate of functional decline in PD 
using currently acknowledged clinical rating scales. Drug trials including placebo 
arms provide information on the natural progression of motor symptoms in patients 
with early disease, estimating the rate of progression in drug-naïve PD patients to be 
3.6 to 13.4 points per year, as measured by the UPDRS motor score.114, 115 Using the 
same assessment tool, progression rates in treated patients ranged from 0.7% to 1.5% 
in two longitudinal cohort studies, one of which was population-based.116,117  
Interestingly, subscores for bradykinesia, rigidity, and gait and balance were found to 
progress similarly, while tremor subscores did not worsen over time, possibly 
indicating different underlying pathophysiological processes.116 
Information on the natural long-term disease progression in PD comes from studies 
conducted in the pre-levodopa era, but is limited. In a study by Mjønes, 40% of 
patients developed impairment of work ability within the first four years of disease 
duration.118 Hoehn and Yahr, in their classic article, reported that 37% of patients 
with PD had reached stage stage III or above within four years of disease duration, 
while 34% of those with a disease duration for ten years or more still were in stage I 
or II.82 Surprisingly, more recent studies suggest that the rate of functional decline is 
similar in treated patients. Müller et al. studied the progression of Hoehn and Yahr 
stages in patients with pathologically confirmed PD and found no patient with 
progression to Hoehn and Yahr stage III within the first year of motor onset.119 In the 
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same study, median duration from debut to Hoehn and Yahr stage II and III was 3 
years and 5.5 years, respectively, similar to the results published by Hoehn and Yahr. 
In a prospective long-term study following treated PD patients for 15 years, the mean 
UPDRS ADL score was 18 in on- and 24 in off-state, and the average Hoehn and 
Yahr stage was 3.8 and 4.1, respectively.113 The authors also compared data on the 
Hoehn and Yahr staging in their patients with those from the pre-levodopa study by 
Hoehn and Yahr and found no differences in long-term results. They concluded that 
modern treatment does not lead to significant long-term benefit in patients with PD. 
There is a remarkable interindividual variation in the progression of PD, which has 
resulted in numerous studies investigating predictors of more or less rapid decline in 
the disease. Hoehn and Yahr, similar to others, suggested that the progression of the 
disease might be slightly less rapid when tremor is the initial symptoms, at least 
during the first ten years of disease duration.82 They found no association between 
age at onset of the disease, gender, or family history, and the rate of disease 
progression in their cohort. In contrast, higher age at disease onset was a major 
determinant of the course of the disease in the Sydney multicentre study, while other 
features including balance problems and symmetrical disease onset were not.120 In a 
case control study, age at onset but not exposure to chemicals and herbicides, well-
water drinking, rural living, or smoking was associated with more rapid progression 
to Hoehn and Yahr stage III.121 In a population-based study, a diagnosis of dementia, 
higher disability and longer disease duration predicted more impaired motor function, 
while age at onset did not.116 Marras et al. reviewed these and other studies to 
summarize evidence on predictors of disease progression in PD.122 Of more than 450 
articles obtained for review, only 13 met the authors’ criteria for inclusion, including 
prospective and longitudinal design. However, of the included studies, many had 
methodological weaknesses, leading to inconsistent or conflicting evidence on 
several potential risk factors of functional decline, including age, age at onset, disease 
duration, and disease subtype. Thus, uncertainty remains about the prognostic 
importance of most factors. 
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1.9.2 Motor complications 
During the course of the disease, a considerable portion of patients with PD develops 
motor complications. These comprise dyskinesias, which are episodes of abnormal 
involuntary movements involving head, trunk, and limbs, and motor fluctuations, 
describing a transient decline in motor performance. Both dyskinesias and motor 
fluctuations increase in frequency with increase in disease duration.  
In clinic-based studies, approximately 40% of patients developed motor problems 
within four to six years after disease onset.123 Hely et al. reported dyskinesias in 94% 
and “end of dose failure” in 96% of patients with mean disease duration of about 17 
years.113 However, these may be overestimates of motor complications due to 
selection bias. Population-based studies are consistent in their finding of substantially 
lower prevalence rates of motor complications in PD.107, 124 In a community-based 
study, 78% of the patients did not experience motor fluctuations after over 6 years of 
levodopa treatment.124 In another population-based study from England, 28% of 
levodopa-treated patients suffered from dyskinesias and 40% from response 
fluctuations after about seven years of disease duration.107  
The risk of developing motor complications has been linked to age of onset, disease 
duration and severity, and levodopa dosage. Patients with younger age at disease 
onset have consistently been found to better respond to levodopa treatment than those 
with late-onset PD, but at the expense of increased dyskinesias and motor 
fluctuations.125 Several clinical trials have shown that those using levodopa only are 
at higher risk to develop motor complications compared to patients treated with 
dopamine agonists alone or in combination with levodopa. There is now compelling 
evidence that non-physiological, pulsative stimulation of dopamine receptors by 
levodopa induces motor fluctuations and dyskinesias, possibly due to changes in gene 
expression which subsequently lead to changes in signaling proteins, neuropeptides, 
and neurotransmitters, resulting in alterations in firing pattern and dopamine 
responsitivity.126 
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1.9.3 Non-motor symptoms 
Most patients with PD will suffer from non-motor problems during the course of the 
disease. In a cross-sectional study of 199 patients with PD, only 12% had no non-
motor problems after seven years of disease duration.127 While the majority of these 
symptoms become more frequent in later stages of the disease, others may occur 
independently from disease duration and even precede the clinical onset of motor 
symptoms. Sleep disturbances, autonomic dysfunction, olfactory deficits, pain, and in 
particular a wide range of neuropsychiatric problems including cognitive impairment 
may lead to substantially reduced functioning and quality of life.8 
1.9.3.1 Cognitive impairment and dementia 
While severe dementia is not typical at disease onset, cognitive impairment may be 
present even in early stages of PD. Impairment in a range of neuropsychological tests 
was found in a series of 91 PD patients with mean disease duration of less than two 
years,128 and in a community-based study more than half of non-demented patients 
had some form of cognitive impairment.129 In another community-based survey in 
early PD, 36% of the patients had evidence of cognitive impairment.130 The cognitive 
profile in patients with the disease varies somewhat, but executive impairment, 
including working memory and attention shift, and eventually visuospatial 
dysfunction characterize early cognitive impairment in PD.131 In a study of 42 PD 
patients with mild cognitive impairment, 20% had dominant memory deficits, 30% 
exhibited predominantly executive impairment, and 50% had a more global cognitive 
impairment.129 
The cognitive impairment in patients with PD is progressive. In a recently published 
population-based study, the mean annual decline on the MMSE in 129 patients with 
PD was found to be one point. However, while the change in score for nondemented 
patients was small, patients with dementia declined with 2.4 points per year.132 With 
advance in PD, there is an increase in the severity and range of cognitive deficits, 
probably reflecting the involvement of cortical structures. Based on results from large 
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community-based studies using standardized cognitive assessment and DSM-IIIR 
criteria, prevalence rates of dementia range from 23% to 41%.133 However, as 
dementia is associated with increased mortalility,134 cross-sectional studies are likely 
to underestimate the true frequency of dementia in PD (PDD). Following de novo 
patients with PD in 5 years, an Australian study estimated a cumulative prevalence 
rate of 36%. In a population-based survey of 224 PD patients with mean disease 
duration of 9 years at baseline, the cumulative prevalence of dementia after 8 years of 
follow-up was as high as 78%.135 The risk for developing dementia is up to 6-fold 
higher in PD than in non-PD subjects,136 and about 10% of patients with PD develop 
dementia per year.136, 137 Overall, about 3-4% of patients with dementia have PDD.138 
Prospective studies indicate that advanced age rather than higher age at onset is a risk 
factor for PDD.135,139, 140 Other factors that are independently associated with 
increased risk for incident dementia in PD are mild cognitive impairment and severity 
of parkinsonism, particularly axial symptoms like postural instability and speech 
problems.135, 139-141 
1.9.3.2 Fatigue 
Fatigue is a subjective experience that can be defined as an overwhelming sense of 
tiredness, lack of energy, or feeling of exhaustion. It is frequently seen in the general 
population, both in developing and developed countries,142 but is significantly more 
prominent in several neurologic, psychiatric and systemic diseases.143, 144 Although 
fatigue is associated and may overlap with depressive symptoms, it is distinguishable 
from depression in which lack of self-esteem and despair or feelings of hopelessness 
are prominent features.145 It is also different from apathy which is dominated by lack 
of motivation with reduced goal-directed behavior, diminished goal-directed 
cognition, and decreased emotional engagement.146 
Fatigue is one of the most common and most disabling non-motor problems in PD 
and has substantially negative impact on cognitive and physical function, and quality 
of life in patients with the disease.147, 148 In a clinic-based study, 58% of patients with 
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PD reported fatigue to be among their three most disabling symptoms, and almost 
one-third rated fatigue as their most disabling symptom. As in other diseases, fatigue 
in PD may occur as a physical or mental problem, and both dimensions of fatigue are 
more prominent in PD compared to age-matched control, but are not correlated with 
each other.91 Underlying causes of fatigue in PD are poorly understood. Pathological 
cytokines in certain areas of the brain may be implicated in the etiology of fatigue in 
patients with PD.149 With SPECT, correlations between fatigue and reduced perfusion 
of frontal lobes in patients with PD were found.150 Findings from several studies 
conducted during the recent years indicate that dopaminergic deficiency may at least 
partially contribute to mental and physical fatigue in PD. In a double-blind, placebo-
controlled crossover study, levodopa significantly improved physical fatigue in 25 
patients with PD.151 In another study, pergolide, an agonist of both D1 and D2 
dopamine receptors, but not bromocriptine, which has high and selective affinity to 
D2 dopamine receptors, reduced fatigue in patients with PD. The authors concluded 
that a functional correlation between D1 receptors and fatigue may exist in PD.152 
Rather few clinical studies have focused on fatigue in patients with PD, and thus 
knowledge on the clinical development of this important non-motor feature is limited. 
As other non-motor symptoms, also fatigue may precede the onset of the disease. In 
their original article, Hoehn and Yahr listed generalized fatigue as the presenting 
symptom in 2% of patients with PD.82 In patients with more advanced disease, cross-
sectional studies found prevalence rates between 40% and 56%, and the frequency of 
fatigue was found to be still higher (75%) during off-state (table 4).153 The latter 
observation suggests that the perception of fatigue changes in parallel with motor 
fluctuations. This may further support an involvement of dopaminergic transmitter 
systems in the etiology of fatigue in PD. In contrast, while findings on the 
relationship between fatigue and disease severity where somewhat controversy, 
clinical studies found associations with other non-motor problems such as depression 
and cognitive impairment, which suggests underlying non-dopaminergic 
pathology.154 However, in a study of 66 PD patients without depression and 
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dementia, still 50% suffered from fatigue.155 This was twice as much as in the general 
population and in patients with severe coxarthrosis.  
Prospective longitudinal studies of fatigue in PD are not conducted. The only 
retrospective longitudinal survey we are aware of, was questionnaire-based and 
followed a rather small cohort of 26 patients.156 Despite the methodological 
limitations of this study, its main finding of persistence of fatigue in the majority of 
patients was interesting, suggesting that fatigue in the vast majority of patients might 
be a direct consequence of disease related pathological changes. 
Table 4. Prevalence of fatigue in PD 
Investigator (year) Sample Number Disease 
duration (yrs) 
Prevalence 
(%) 
Hoehn and Yahr (1967) Clinic-based 183 at onset 2% 
Van Hilten et al. (1993) Clinic-based 90 6.4 43% 
Karlsen et al. (1999) Community-
based 
233 9.0 44% 
Shulman et al. (2001) Clinic-based 99 6.9 40% 
Witjas et al. (2002) Clinic-based 50 12.7 56%-75% 
Herlofsen et al. (2003) Clinic-based 66 7.3 50% 
 
1.9.3.3 Other neurobehavioral disturbances 
Neuropsychiatric problems are common in PD. In a population-based study of 139 
patients with PD, 61% suffered from at least one neuropsychiatric symptom after 12 
years of disease duration.157 Of importance, charting the frequency of cognitive 
impairment, dementia, and fatigue was not part of this investigation. The most 
common behaviors found were depression (38%) and hallucinations (27%).  
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Depressive symptoms are significantly more common in PD than in age-matched 
controls and patients with other chronic diseases.158, 159 In most population-based 
cross-sectional surveys, depression rates range from 20% to 50%. Meara and 
colleagues, however, reported depression in 64% of PD patients in their community-
based cohort from North Wales.160 This variation is likely to be the result of 
methodological differences used in the respective studies. In most patients, depressive 
symptoms are of mild to moderate severity, while major depression is less frequent. 
In a population-based study, only 7.7% met DSM-III criteria of major depression, 
while 45.5% had mild depressive symptoms.159 In those with dementia, however, the 
portion of patients suffering from major depression is substantially higher.161 Despite 
the high frequency of depressive symptoms, suicide is not more common in patients 
with PD compared to the general population.  
Those with a history of depression and reduced functional activity are at risk for 
development of both major and minor depression.162, 163 Other features such as 
cognitive impairment, female gender, and age are controversial risk factors for 
depression in PD. The relationship to disease severity is not as clear as in other 
neuropsychiatric problems, as a considerable portion of patients develop depressive 
symptoms shortly after or even before the motor manifestation of the disease.164  
The reasons underlying depression in PD are unclear, but there is evidence for 
involvement of dopaminergic, noradrenergic, and serotonergic systems.165 
Neuroimaging studies have shown changes in metabolism in frontal lobes, 
particularly on the left side,166 and reduced binding to cortical serotonin receptors, 
indicating postsynaptic dysfunction. More recently, depressive symptoms were 
shown to inversely correlate with reduced dopaminergic and noradrenergic binding in 
the locus coeruleus and several regions of the limbic system.101 
Hallucinations in patients with PD rarely occurred before the introduction of 
dopaminergic treatment.167 Dopaminergic agents are therefore understood as an 
important cause to psychotic symptoms and abnormal behavior in PD. However, in 
several prospective studies no association between hallucinations and dosages of 
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dopaminergic agents or treatment duration could be found.168, 169 In contrast, other 
factors such as age, disease severity, and most consistently cognitive impairment 
were identified as risk factors for hallucinations in patients with PD.167 Due to the 
latter observation, a current theory is that hallucinations origin from a combination of 
dopaminergic stimulation and a more widespread cerebral involvement. Thus, an 
increase in frequency is expected as the disease progresses. 
Reported prevalence rates of hallucinations vary, most likely due to differences in 
patient selection and study design, and range from 10% to 39%.167 In a population-
based study from England, 23% of 124 patients with PD suffered from hallucinations 
after 6 years of disease duration, compared to 26.6% of patients with a mean disease 
duration of 12 years in a Norwegian cohort.168 Longitudinal studies of hallucinations 
in PD are rare. In a prospective survey of 89 PD patients with a mean disease 
duration of about 10 years at baseline, hallucinations were progressive and persistent, 
affecting 33% at study entry and 44% of patients four years later.170 In the same study 
and others,171, 172 visual hallucinations were found to be the most common form, 
while auditory, olfactory and tactile hallucinations were less frequent and usually 
present together with visual hallucinations. Although the insight is and remains 
retained in most patients with PD, hallucinations are one of the main features leading 
to hospitalization and nursing home placement.173   
Symptoms of apathy, similar to the sense of fatigue, may overlap with those of 
depression, but there is evidence that these conditions are separable from each 
other.146, 174 Apathy is common in several neurodegenerative diseases, particularly in 
progressive supranuclear palsy (PSP), in which up to 80% of patients are affected, 
while coexisting depression is rather rare. Across diagnostic groups, functional 
disturbances of the anterior cingulum, which is reciprocally connected to limbic, 
frontal, and basal ganglia structures, were found to be related to apathetic behavior.175  
There is a lack of longitudinal studies of apathy in PD, and thus there is an 
uncertainty whether and how characteristics of apathy may change over time. 
Observed frequency rates of apathy vary substantially, ranging from 17% to 70%. 
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This variation has been attributed to use of different rating scales of apathy, different 
cut-off values, and other methodological differences.175 In the so far largest and only 
population-based study of apathy in PD, 16.5% were diagnosed with apathy after 
12.6 years of disease duration.157 Results from several cross-sectional studies suggest 
that apathy is strongly associated with cognitive impairment and dementia, and also 
executive dysfunction.146, 174, 176 Thus, in those with advanced PD higher prevalence 
rates of apathy are expected compared to patients with early disease. 
1.9.3.4  Sleep disorders 
During the last decade, scientific research on sleep disturbances has resulted in 
achievement of thorough knowledge on regulation mechanisms of the sleep/wake 
mechanisms.177 It is now clear that several brainstem nuclei and their communicating 
pathways in the ascending arousing system through the hypothalamus and thalamus 
to the cortex play key roles in sleep disorders. As Lewy bodies and cell loss are 
found in these areas in PD, it is anticipated that disturbances of sleep and alertness, 
including insomnia, hypersomnia, and parasomnias, are experienced by a large 
number of patients with PD and other diseases belonging to the group of α-
synucleinopathies, such as MSA.178 In addition to pathological changes in brain areas 
crucial for regulation of sleep and awakeness, other conditions may contribute to 
sleep problems in patients with PD as well. Dopaminergic drugs, particularly 
dopamine agonists, have been linked to different sleep complaints including 
insomnia, excessive daytime somnolence, and sudden sleep attacks.179, 180 It may 
be possible that the neurodegenerative process underlying PD makes the patients 
vulnerable to drug induced sleep fragmentation, as well as hypersomnia. Also 
coexisting motor (e.g. nocturnal bradykinesia) and non-motor problems (e.g. 
depression, hallucinations, nocturia), as well as other conditions like obstructive 
sleep apnea may worsen sleep quality in PD. In general, sleeping problems increase 
during the course of the disease, both with regard to their frequency and severity. In 
two previous studies, 74% and 93% of patients with PD reported some kind of sleep 
disturbances.181, 182  
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Insomnia is the most common sleeping problem in PD. In a population-based study, 
60% of the patients complained about nocturnal sleeping problems after 9 years of 
disease duration.183 In most of them, sleep fragmentation and early awakening were 
the major problems, while falling in sleep was not. In the same population, these 
sleeping problems were found to be main contributors to reduced quality of life.184 
Severe hypersomnia, often called excessive daytime sleepiness (EDS), is also 
common in PD.185 Evidence suggests that daytime somnolence in PD is not a 
consequence of nocturnal sleeping problems.186 EDS has been found in 15% of PD 
patients in a population-based cohort with mean disease duration of nine years. 
Results from a longitudinal study of the same population suggest that EDS in PD is a 
persistent complaint when once experienced.186 EDS is strongly associated with 
disease severity, indicating that underlying cerebral changes themselves may be of 
major importance.186 However, dopaminergic agents may contribute as well.187 
REM sleep behaviour disorder (RBD) is a parasomnia characterized by prominent 
motor activity due to loss of the normal skeletal muscle atonia during REM sleep. 
Patients with idiopathic RBD have been shown to be at increased risk to develop PD 
and other α-synucleinopathies, and thus RBD may be an early sign of an evolving 
synucleinopathy.188 It is particularly common in patients with MSA and DLB.188 In 
PD, up to one-third of patients are affected.189, 190 The clinical main features of RBD 
are vocalizations and movements of limbs and body. They can vary in intensity and 
duration, and complex behaviors such as walking and even punching are described, 
potentially leading to injuries of patients themselves or their partners.  
The syndromes of restless legs (RLS) and period limb movements during sleep 
(PLMS) are other parasomnias that may be associated with and more common in PD. 
In a case-controlled study from India, 7.9% of PD patients at five years of disease 
duration complained about RLS compared to only 0.8% of control subjects.191 In 
comparison, others reported a 19.5% prevalence in PD at a mean disease duration of 
9.1 years.192 Because plasma ferritin concentrations were lower in RLS with PD than 
in idiopathic PD, low ferritin levels have been suggested to contribute to the 
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development of RLS in PD. Disturbances in central dopaminergic systems, however, 
seem to play a major role in the etiology of RLS in patients with PD.193 
1.9.3.5 Autonomic disturbances 
Although autonomic dysfunction, particularly orthostatic hypotension, is generally 
accepted to be a clinical marker of atypical parkinsonian disorders such as MSA, 
increasing evidence suggest that it is a frequent characteristic also in patients with 
PD. 
A recent study of de novo patients with PD found decreased cardiac radioiodinated 
metaiodobenzylguanidine (MIBG) uptake, indicating that latent sympathetic nervous 
dysfunction is already present in patients with early, untreated PD.194 In the same 
study, MIBG uptake and blood pressure responses decreased with increased disease 
severity, suggesting that vasomotor cardiac dysfunction is associated with the 
severity of the disease. This is in line with clinical observations of an increase in 
autonomic disturbances as the disease progresses. Symptomatic hypotension is rare in 
early PD. In a prospective study of 51 de novo patients with PD, only one showed 
clinical symptoms of hypotension.195 In contrast, in a prospective clinic-based survey 
of patients with 6 years of disease duration and more advanced disease, 15.4% 
complained about symptomatic orthostatic hypotention. Other frequently experienced 
autonomic symptoms in this cohort were hypersalivation (14%), sexual dysfunction 
(18%), urinary problems (22%), sweating disorder (24%) and constipation (59%).  
Surprisingly, except for cardiovascular dysfunction, autonomic symptoms do not 
correlate with the duration and severity of the disease, nor age at onset in most 
studies.196 In contrast, advanced age was associated with autonomic failure in some, 
leading to the suggestion that an disease related amplification of aging effects may 
contribute to autonomic disturbances in PD.196, 197 
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1.9.3.6 Olfactory dysfunction 
Olfactory dysfunction in PD includes impairment of odor detection, differentiation, 
and identification, and is persistent and not influenced by drug treatment.198 While 
most previous studies did not find any association between olfactory deficits and 
severity of parkinsonism, more recently published papers conclude that there is at 
least some relationship to disease severity in PD, particularly during the early stages 
of the disease.199, 200 Prevalence rates of hyposmia in PD vary depending on which 
approach is used to identify the olfactory dysfunction. Most of the patients with PD 
showing deficits in olfactory tests are unaware of a smell disorder.201 In a German 
study, 24% of 37 patients with PD reported to have had impaired olfactory function 
prior to the diagnosis of PD, 38% experienced subjective smell loss at the time or 
after diagnosis of PD, and the remaining 38% had subjectively normal olfaction after 
about 5 years of disease duration.200 In contrast, based on olfactory testing, all 
suffered from impaired olfactory function with more than 50% of the patients 
diagnosed with anosmia. 
In the light of Braak’s hypothesis of a stagewise progression of pathogical changes in 
PD, indicating presymptomatic lesions in the olfactoric tract, attention has been 
drawn to patients primarily diagnosed with idiopathic hyposmnia. These are now 
shown to be at rather high risk to develop PD later during life.202 Of 40 hyposmic, 
asymptomatic first-degree relatives of PD patients, 10% developed clinical PD within 
two years of follow-up. In addition, baseline 123β-CIT binding ratios of these 
patients were strongly reduced, indicating a subclinical degenerative process within 
the dopaminergic nigrostriatal system. Interestingly, in the remaining non-
parkinsonian relatives with hyposmia the rate of decline in dopamine transporter 
uptake was significantly increased compared to relatives without olfactory 
dysfunction. 
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1.10 Treatment of PD 
There is no causal treatment available, and thus pharmacological therapy is still 
aimed at controlling motor signs and, to a less extent, non-motor symptoms in PD. 
Information about the disease and treatment strategies, as well as patient 
organisations, should be given as soon as possible during the course of the disease. 
Patients also should be informed about non-pharmacological treatment strategies of 
motor and non-motor symptoms, including physiotherapy and speech therapy. 
1.10.1 Drug treatment of motor symptoms 
Levodopa is a precursor of dopamine that is actively transported across the gut wall 
and passes the blood-brain barrier. It is taken up by dopaminergic neurons and 
decarboxylated to dopamine in the presynaptic terminal where it replaces dopamine 
lost by degeneration of substantia nigra. Levodopa is usually given in combination 
with a peripheral decarboxylase inhibitor (carbidopa or benserazide) to reduce 
peripheral side effects and to improve therapeutic effects. Although a wide range of 
differently acting agents has been developed since its introduction in the 1960s, 
levodopa is still considered to be the most effective drug therapy in PD.6 The vast 
majority of patients with PD starting treatment with levodopa experience good to 
excellent functional benefit. However, with longterm use, levodopa therapy is 
associated with more frequent development of motor fluctuations and dyskinesias 
compared to other dopaminergic drugs, probably due to pulsative stimulation of 
dopamine receptors. As patients with older age at disease onset are less likely to 
develop motor complications and have a rather short life-expactancy, levodopa is the 
preferred treatment in these patients. 
Dopamine agonists directly stimulate postsynaptic dopamine receptors without 
undergoing oxidative metabolism.203 They have a longer duration of action than 
levodopa and do thus not expose dopamine receptors to rapidly fluctuating levels of 
stimulation. Such unphysiological stimulation is thought to underlie the development 
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of motor complications. Several controlled trials have shown that initial therapy with 
dopamine agonists is associated with less rapid development of motor fluctuations 
and dyskinesias compared to initial treatment with levodopa.204 The most recently 
developed dopamine agonists mainly stimulate D2- receptors, leading to less frequent 
side-effects than traditional dopamine agonists such as pergolide. Most common side 
effects are nausea, vomiting, and orthostatic hypotension. To avoid or reduce these, 
the dose of dopamine agonists is usually increased slowly, particularly in newly 
diagnosed patients. Dopamine agonists may also be given to patients with advanced 
disease who experience loss of efficacy during levodopa therapy. However, given in 
monotherapy, dopamine agonists are preferred in patients with younger age.205 
Catechol-O-methyltransferase (COMT) inhibitors increase half-life and 
bioavailability of levodopa by inhibiting its conversion into 3-O-methyl-dopa. 
Entacapone is a peripheral COMT inhibitor and currently approved for adjunctive 
treatment in patients with motor fluctuations. Administered in combination with 
levodopa it reduces daily off-time and increases on-time. Because entacapone 
enhances the dopaminergic effect of levodopa, vomiting, dizziness, and particularly 
dyskinesias are typical side effects. 
MAO-B inhibitors like selegiline inhibit the degradation of dopamine in the 
striatum. Several studies show less rapid disease progression in patients treated with 
selegiline,206, 207 which may indicate neuroprotective properties, but results are not 
conclusive. Selegiline has only weak symptomatic effect and is generally well 
tolerated. However, due to metabolization to metamphetamine, it may increase blood 
pressure, sleep problems, and euphoria. Used in adjunctive therapy it also may 
potentiate side effects of other antiparkinsonian drugs. Recently, another irreversible 
MAO-B inhibitor, rasagiline, has been introduced in the treatment of PD.208 
Rasagiline has shown similar clinical effects as entacapone with respect to 
improvement of motor function and motor fluctuations. It is approved for use as 
initial monotherapy and adjunctive treatment in moderate-to-advanced PD.        
Unlike selegiline, rasagiline is metabolized to aminoindan and thus free from 
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amphetamine-related side effects. Also rasagiline may have disease-modifying 
properties, but further studies are needed before firm conclusions can be drawn. 
Amantadine and anticholinergic drugs are no longer recommended for routine use 
in PD in Norway due to limited symptomatic effect and an unfavorable profile of 
adverse effects including worsening of behavioral and autonomic function.  
1.10.2 Drug treatment of non-motor symptoms 
In recent years, several placebo-controlled trials indicated that cholinesterase 
inhibitors (ChEI) improve cognition and psychiatric symptoms, as well as global 
function in patients with PDD.209 In the so far largest randomized, placebo-controlled 
trial including 541 patients with PDD, treatment with rivastigmine resulted in a 
moderate improvement in global ratings of dementia, cognition, and behavioral 
symptoms after 24 weeks of follow-up.210 However, the majority of patients who 
were treated with rivastigmine (80.2%) had no clinically meaningful improvement. 
Interestingly, the occurrence of hallucinations in rivastigmine-treated patients was 
half of that in untreated subjects, indicating that ChEI may have antipsychotic 
properties. The most frequent adverse events observed in treatment with ChEI were 
nausea, vomiting, and worsening of tremor.  
Clinical experience and epidemiological studies suggest that hallucinations in PD are 
mainly visual and non-threatening, and associated with advanced disease. Although 
the underlying pathophysiology is poorly understood, treatment with dopaminergic 
agents is thought to play a major role. However, also other medical conditions like 
infections, fever, and electrolyte disturbances may exacerbate hallucinations and 
should be eliminated before dose reduction of dopaminergic agents is considered. 
Typical antipsychotic drugs may improve hallucinations, but also worsen 
parkinsonism due to their antidopaminergic properties. Therefore, treatment with 
atypical antipsychotics, which are characterized by rather low D2-receptor 
antagonism, is broadly recommended in PD patients with hallucinations. Clozapine 
has been shown to reduce hallucinations without worsening motor symptoms, but is 
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associated with a range of side effects. Because it also may lead to life-threatening 
agranulocytosis, frequent monitoring is required. This strongly limits its use in 
everyday practice. Therefore, other atypical antipsychotic drugs, particularly 
quetiapine, are generally preferred in treating hallucinations in PD. However, it is 
worthwile to note that atypical antipsychotics including risperidone and olanzapine 
failed to significantly improve hallucinations in PD in a number of controlled trials. 
In line with this, a recently published double-blind, placebo-controlled trial in PD 
patients with hallucinations revealed no benefit of quetiapine compared to placebo.211 
Depressive symptoms and their pharmacological treatment with serotonine reuptake 
inhibitors (SSRI) are common in PD. Also tricyclic antidepressants (TCA) are 
used in the treatment of depression in PD. However, the number of well-designed 
clinical trials of antidepressants in patients with PD is limited. A recent meta-analysis 
concluded that both active treatment and placebo improved depressive symptoms to a 
similar extent.212 In contrast, results from the same study indicated that patients with 
PD may benefit less from antidepressants than elderly depressed patients without the 
disease. 
Modafinil is a wakefulness promoting agent approved for use in narcolepsy and has 
recently been investigated for efficacy and tolerability in PD patients with EDS. The 
results show good tolerability in patients with PD, but some inconsistency regarding 
efficacy, with improvement in subjective but not objective measurements of daytime 
somnolence.213, 214 However, in the most recent and so far largest double-blind, 
placebo-controlled trial, modafinile failed to improve EDS measured by both the 
Epworth Sleepiness Scale (ESS) and the multiple sleep latency test (MSLT).215 
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1.10.3 Surgical treatment 
Surgical treatment in PD is still reserved to patients with both advanced disease and 
motor complications. Although lesioning surgery, particularly by pallidotomy, is 
considered efficacious in treatment of PD, deep brain stimulation (DBS) has 
become the gold standard in surgical treatment of PD during the last decade.216 Main 
advantages of DBS compared to ablational surgery are its reversibility and the 
possibility of adjustment over time. DBS of the subthalamic nucleus (STN) has 
become the most widely used surgical treatment of motor complications in PD. 
Careful patient selection is important to achieve good clinical response after STN 
DBS. Younger age and good levodopa-responsiveness predict a favorable outcome. 
Recent studies indicate that DBS of the STN provides substantial long-term benefits 
regarding motor function and motor complications. Five years after STN 
implantation, motor function measured by UPDRS III was still improved 54% “off”-
medication and even 73% “on” drug.217 Severity of levodopa related motor problems 
was decreased by 67% and daily levodopa dosages reduced by 58%. However, STN 
DBS does not halt disease progression based on results from neuroimaging study 
measuring disease progression by 18F florodopa PET.218 DBS of the globus pallidus 
interna (GPi) provides similar improvement of motor function and motor 
complications compared to STN stimulation, but has less impact on drug dosages.219 
Treatment with DBS of the thalamic ventralis intermedius nucleus (Vim) is less 
common in PD, but may be helpful in those with predominant resting tremor.  
During the 1990s, several open studies reported improvement of motor function after 
transplantation of embryonic dopaminergic grafts into the putamen and caudate in 
PD. However, fetal nigral transplantion is currently far from being a treatment option 
in PD after two more recently published double-blind, sham-controlled trials reported 
no overall treatment benefit.220, 221 In contrast, high frequencies of adverse events, 
particularly “off”-medication dyskinesias, were observed in up to 56% of 
transplanted patients within two years after surgery. 
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1.11 Prognosis and socioeconomic consequences of PD 
PD is chronic and progressive, and currently incurable. No treatment is proven to halt 
the progression of the disease. Life expectancy is decreased despite modern 
treatment. In their classic article, Hoehn and Yahr reported a standardized mortality 
ratio (SMR) of 2.9.82 SMR derived from later studies range from 1.3 to 4.1.222, 223 
Methodological differences are likely to account for this variation. In a study 
identifying incident cases of PD in Olmstead County between 1976 and 1995, median 
survival of patients was 10.3 years.224 In the Sydney Multicentre Study following de 
novo patients randomly assigned to levodopa or bromocriptine, the median time from 
onset of the disease to death was 12.2 years.113 Interestingly, patients originally 
assigned to levodopa survived longer than those using bromocriptine. Disease 
severity, dementia and, with some inconsistency, age are independent risk factors for 
increased mortality.222, 223 The cause of death in patients with PD are often related to 
immobility, and fatal infections are not unusual.225 
Economic investigations of the costs of PD have not been done in Norway yet, but 
several studies from Western and Northern European countries show that the disease 
is costly for patients and the society.226-228 In a Swedish survey, the total annual cost 
of the disease was estimated to be 13,800 Euros per individual.226 Due to the 
progressive nature of PD, costs increase with disease severity. Direct annual costs 
were estimated to be nearly 30,000 Euros for those in Hoehn and Yahr stage V, and 
nursing home placement was associated with a cost increase of approximately 500% 
in English patients.228 Due to the aging population, the economic burden of PD is 
expected to further increase in future. 
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2 Aims of the study 
The primary objectives of this thesis were to describe and achieve a better 
understanding of aspects related to the clinical disease progression in 
Parkinson’s disease (PD). To obtain this information we have 
 
• in study 1 examined the frequency of cigarette smokers in a population-
based cohort of patients with PD and two control groups, and investigated 
the progression of parkinsonism, cognitive impairment, and mood in 
smoking and nonsmoking patients with PD; 
 
• in study 2 evaluated whether mental fatigue is a symptom that appears 
independently from other clinical features in patients with PD, and studied 
whether fatigue is a persistent complaint over time in these patients; 
 
• in study 3 investigated various risk factors for and the rate of progression of motor 
symptoms and disability in a population-based cohort of patients with PD; 
 
• in study 4 investigated how changes in motor subtype influence the risk for 
incident dementia in patients with PD. 
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3 Methods 
3.1 Patient selection and follow-up 
Between September 1992 and May 1993, a population-based prevalence study was 
conducted in Rogaland county, Western Norway.16 To achieve complete case 
ascertainment, an extensive search in hospital files was provided, and information 
from all relevant sources in the study area including general practitioners, nursing 
homes, district nurses, health workers and the Rogaland Parkinson’s Disease Society 
was assessed. Of about 400 patients examined by neurologist with special interest in 
movement disorders, 245 patients were diagnosed with PD according to published 
diagnostic criteria.229 The crude prevalence was 110.9 per 100,000 inhabitants and 
102.4 per 100,000 after adjusting for age to a standard European population.  
Of the 245 patients diagnosed with PD at baseline, 239 patients were able and wanted 
to participate in the study and constituted the patient cohort investigated in study 1. 
233 patients of these were assessed for fatigue and included in study 2. The data of 
232 patients with PD were available for analysis of risk factors and the rate of disease 
progression in study 3. Of these 232 patients, 171 were non-demented at baseline. 
These 171 patients were included in study 4. Patients were invited by letter to 
participate in follow-up examinations in 1997 and 2001. A total of 144 patients 
attended the first follow-up visit in 1997, and 89 patients were examined in 2001. 
3.2 Control subjects (study 1) 
Study 1 also used data from two control groups of same age and sex distribution as 
the PD cohort, examined in 1993. While one control group included 100 healthy and 
well-functioning elderly people derived from routine-visits at their general 
practitioners, the other consisted of 100 patients with another chronic disease 
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(diabetes mellitus), selected randomly from the diabetes outpatient-clinic at the 
(former) Rogaland Central Hospital. 
3.3 Diagnosis of PD 
To achieve both high sensitivity and specificity in case ascertainment, a new 
diagnostic classification was used to diagnose clinical possible, probable, and definite 
PD.229 
I. Clinical definite idiopathic PD 
The patient presents resting tremor and at least two of the following signs: 
bradykinesia, rigidity, or postural abnormalities. In addition, unilateral onset and 
asymmetric development are mandatory, as well as good to excellent response to 
dopaminergic agents. Neither atypical signs or symptoms nor changes on computed 
tomography (CT) or magnetic resonance imaging (MRI) of the head are accepted. 
II. Clinical probable idiopathic PD 
Patients must fulfil at least two of four cardinal signs, but tremor at rest is not 
mandatory in this subgroup. A maximum of one the following atypical features may 
be present: (a) early mild dementia or clinically relevant autonomic failure, (b) 
symmetrical disease presentation, (c) only a moderate response to dopaminergic 
treatment, or (d) other atypical signs or symptoms indicating another parkinsonian 
disorder. 
III. Clinical possible idiopathic PD 
The patient must present at least two of the four cardinal signs. In addition, response 
to dopaminergic agents should be at least moderate. Mild to moderate dementia and 
autonomic disturbances may be allowed. A history indicating symptomatic 
parkinsonism due to drug treatment will lead to exclusion from this category. 
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3.4 Assessment of parkinsonism and disability   
All patients were examined by neurologists experienced in diagnostics and treatment 
of movement disorders. The same standardized examination program was applied at 
all study visits, including the Unified Parkinson’s Disease Rating Scale (UPDRS), the 
Hoehn and Yahr staging, and the Schwab and England scale. These measurement 
instruments of motor function and disability are described in detail in section 1.8 
“Assessment of disease severity and progression in PD”.  
In study 2 to 4, the disease subtype of the individual patient was classified as tremor-
dominant (TD), indeterminate, or postural-instability gait difficulty (PIGD),102 based 
on predominant motor symptoms in the UPDRS ADL and motor subscore: total 
tremor score was calculated as the mean tremor score in UPDRS subscale II and rest 
tremor score for face, upper and lower limbs, and postural or action tremor of both 
hands in UPDRS subscale III. Total PIGD-score was defined as the mean of the items 
falling, freezing, walking difficulties in UPDRS II, and gait and postural instability 
scores in UPDRS III. Disease subtype was classified as PIGD when the ratio of total 
tremor score/total PIGD score was equal to or less than 1.0, whereas patients with a 
ratio of 1.5 or more were defined to have TD subtype. When the tremor/PIGD ratio 
was more than 1.0 and less than 1.5 patients were classified to be in the indeterminate 
category. 
3.5 Assessment of smoking habits (study 1) 
Information on smoking habits was collected at baseline from all patients with PD 
and two control groups of healthy elderly and patients with diabetes mellitus. Those 
who did not smoke in 1993 were categorized as smokers. For smokers, pack-years 
were calculated by dividing the average number of cigarettes smoked per day in a 
given time interval by 20 and multiplying by the number of years smoked. To detect 
a possible dose relationship between smoking and progression of PD, smokers were 
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classified into two groups based on the intensity of smoking: mild to moderate (<20 
pack-years) and heavy smokers (20 pack-years and more). 
3.6 Assessment of cognitive impairment and dementia 
At baseline, all patients were assessed with the Mini-Mental State Examination 
(MMSE),84 and a structured interview based on the DSM-III-R criteria was 
performed with their caregivers.230 The Gottfries, Bråne & Steen Dementia scale 
(GBS)231 was completed based on the clinical interview and examination.  
A more extensive cognitive assessment battery was performed at follow-up visits. 
The Dementia Rating Scale (DRS)86 was administered, and patients with a MMSE 
score of 16 or above completed a neuropsychological test battery including tests 
assessing visual memory (Benton Visual Retention Test),232 executive 
functioning/attention (Stroop test),233 and visuospatial functioning (Benton 
Judgement of Line Orientation Test).234 For MMSE and DRS, age- and education-
based cut-off scores were used. Dementia was diagnosed by two of the authors after 
reviewing all the available material, according to DSM-III-R criteria, and based on 
clinical interview, cognitive rating scales, and neuropsychological tests. The 
assessment of symptoms of cognitive dysfunction and dementia was performed blind 
to the motor evaluation. 
3.7 Assessment of fatigue (study 2 and 3) 
At all study visits, information from two different rating scales of patient-perceived 
fatigue was used to evaluate fatigue. First, lack of energy is rated as one of six 
dimensions in the Nottingham Health Profile (NHP), a health-related quality of life 
questionnaire, which has been extensively tested for validity and reliability.235 NHP-
items that were included in the evaluation of fatigue were “I am tired all the time”, 
“Everything is an effort”, and “I soon run out of energy”. In addition, all patients 
were asked to give a evaluation of feeling energetic or fatigued on a 7-point rating 
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scale.154 They were asked if they mostly felt very strong and healthy (1), strong and 
healthy (2), somewhat strong and healthy (3), cannot decide (4), somewhat tired and 
worn out (5), tired and worn out (6), or very tired or worn out (7). Patients who 
reported lack of energy in at least one of three questions on the NHP and scored four 
or more on the seven-point scale were classified as having fatigue. 
To evaluate the validity of this classification, the Fatigue Severity Scale (FSS)88 was 
added to the evaluation program in 2001. Mean FSS score for patients with PD 
suffering from fatigue according to our classification was 5.3 (SD 1.5) versus FSS 
score of 3.7 (SD 1.6) for patients without fatigue. This difference was highly 
significant (p<0.001). 
3.8 Assessment of other non-motor symptoms 
Severity of depressive symptoms was assessed using the Montgomery and Aasberg 
Rating Scale (MADRS)236 and the Beck Depression Inventory (BDI).237 While the 
first instrument is an examiner-rated assessment tool, the latter measures the level of 
patient-perceived depression. Both rating scales have been shown to be reliable, 
sensitive, and valid measurement instruments of depression. 
At all study visits, patients also completed a questionnaire covering both daytime and 
nighttime sleep problems, including excessive daytime sleepiness, insomnia, and 
parasomnia-suspect features such as RBD and PLMS. In 2001, patients were also 
assessed by the Epworth Sleepiness Scale (ESS),238 a validated and widely used 
assessment tool of daytime somnolence. 
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3.9 Statistical analysis 
In study 1, the progression of disease was measured as change in severity of motor 
impairment, disability, mood, and cognitive impairment between baseline 
examination and follow-up visits. Differences in means of changes in symptoms 
between smokers and non-smokers were compared by Students t-test and differences 
in proportions for categorical variables by χ2 tests. For smoking and non-smoking PD 
patients, survival curves were calculated by the Kaplan-Meier method. A Cox 
regression model including adjustment for age in three categories (less than 70 years, 
71-80 years, more than 81 years) and gender was used to calculate the relative risk for 
mortality in the two PD groups.  
In study 2 to 4, Mann-Whitney tests and χ2 tests were performed to compare 
medians and proportions between groups in cross-sectional data. When more 
than two groups were compared, Kruskal-Wallis tests and linear-by-linear association 
tests were used, and Mann-Whitney posthoc tests were performed when the overall 
test was significant. For longitudinal data, we performed logistic regression models 
for correlated data239 to analyse the relationship between dependent and independent 
variables in studies 2 to 4, and to estimate the rate of functional decline over time in 
study 3.  
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4 Results 
Study 1 
We found a 50% higher prevalence of smokers among healthy elderly and patients 
with diabetes mellitus compared to a population-based cohort of patients with PD. In 
contrast, during the follow-up period, there were no significant differences in 
progression of parkinsonism, disability, cognitive impairment, and mood in smoking 
and nonsmoking patients with PD. Mortality was also similar in the two groups. 
 
Study 2 
In PD patients who were followed throughout an 8-year study period, fatigue 
increased from 35.7% in 1993 to 42.9% in 1997 and 55.7% in 2001. Fatigue was 
related to disease progression, depression, and excessive daytime sleepiness (EDS). 
However, the prevalence of fatigue in patients without depression and EDS remained 
high and increased from 32.1% to 38.9% during the study period. For about 44% of 
the patients with fatigue the presence of this symptom varied during the study period, 
as it was persistent in 56% of the patients with fatigue. 
 
Study 3 
Over the 8-year study period, we found a similar mean annual decline in the UPDRS 
motor score and the Hoehn and Yahr staging of 3.1% and 3.2%, respectively. Also 
the UPDRS Activity of Daily Living score and the Schwab and England scale 
changed similarly, with 3.5% and 3.6% per year, respectively. Age, age at onset, 
disease duration, and excessive daytime somnolence at baseline were strong and 
independent predictors of greater impairment in motor function and disabilitity. 
Cognitive impairment at baseline predicted higher disability and higher Hoehn and 
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Yahr staging. Time by age-at-onset interactions were found for the UPDRS motor 
score and the Hoehn and Yahr staging. 
 
Study 4 
Transition from tremor-dominant (TD) to postural instability gait difficulty (PIGD) 
subtype was associated with a more than 3-fold increase in the rate of MMSE decline. 
Compared to patients with persistent TD or indeterminate subtype, the odds ratio for 
dementia was 56.7 (95% CI 4.0-808.4; p=0.003) for patients changing from TD or 
indeterminate subtype to PIGD subtype, and 80.0 (95% CI 4.6-1400.1; p=0.003) for 
patients with persistent PIGD subtype. Patients with TD subtype at baseline did not 
become demented until they developed PIGD subtype, and dementia did not occur 
among patients with persistent TD subtype of parkinsonism. 
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5 Discussion 
5.1 General aspects of methodology 
The primary goal of epidemiological research is to provide information on the 
development, prevalence and progression of diseases, and their associated risk factors 
in the general population. Interpretation of data from epidemiological research is thus 
the basis of increasing our understanding on the etiology of diseases and in 
consequence the starting point for identifying at risk-groups in the population, 
prevention of diseases, development of treatment strategies, and health care planning. 
Because epidemiological data, by definition, refer to the general population and 
reflect characteristics of a representative sample of individuals suffering from a given 
disease, quality of epidemiological research highly depends on diagnostic accuracy 
and completeness of case-ascertainment. 
In PD, the diagnosis during lifetime is still based on disease history and clinical 
examination, as no biomarkers are currently available to prove the clinical diagnosis. 
Therefore, and because PD is characterized by clinical heterogeneity and symptoms 
may overlap with those of other conditions such as atypical parkinsonian disorders 
and symptomatic parkinsonism, use of careful diagnostic criteria is essential to 
provide valid information on the disease. One of the major challenges in PD research 
is to achieve high diagnostic specificy and sensitivity, that is, to include all patients 
with the disease while excluding those not suffering from PD. Diagnostic accuracy 
has particular importance when measuring disease progression in PD. For example, 
inclusion of patients with essential tremor, that is frequently reported to have been 
diagnosed as PD, would lead to an overestimate of the prevalence of the disease, but 
underestimate of the rate of disease progression. In contrast, inclusion of subjects 
suffering from atypical parkinsonian disorders, characterized by rather rapid 
functional decline, would tend to give a worse impression of both the frequency and 
course of the disease. 
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Several autopsy studies from the early 1990s reported poor accuracy in clinical 
diagnosis of PD, with pathological evidence of PD in not more than 76%, even when 
patients were diagnosed by neurologists.240, 241 As a consequence, we applied a new 
diagnostic classification in our studies to diagnose patients with PD at different levels 
of confidence to achieve both high sensitivity and specificy.229 In addition, our 
longitudinal design including re-evaluations after four and eight years made it 
possible to revise the clinical diagnosis in patients who had developed signs and 
symptoms atypical in PD. Of the 245 patients included at baseline, less than 3% were 
rediagnosed as not suffering from PD during follow-up, and of those who underwent 
autopsy (22 patients), all fulfilled neuropathological criteria of PD.242 For the sake of 
comparison, in a clinicopathological study from the United Kingdom, the positive 
predictive value of the clinical diagnosis of idiopathic PD provided by movement 
disorders specialists according to the UK Brain Bank criteria was 98.6%, while 
sensitivity was 91.1%.243  
In addition to achieve high diagnostic specificy and sensitivity, we made great efforts 
to include all patients within the study area. An unfavorable trend of case-
ascertainment in many studies is to include patients based on retrospective review of 
medical records. Such clinic-based data are likely to reflect information from highly 
selected subpopulations with more advanced or more complicated disease, but in 
which the study subjects are still mobile and able to visit the hospital or outpatient-
clinic. Thus, patients not referred to the outpatient clinic, particularly those living in 
institutions, are likely to be underrepresented in such surveys. Several lines of 
evidence support that nursing home placement leads to underrecognition and -
diagnosis of patients with PD.244, 245 About 5% of residents in Norwegian nursing 
homes were found to have clinical PD, 18% of whom were previously 
undiagnosed.244 Therefore, in addition to search in hospital files, case-ascertainment 
in our study was based also on information from the Rogaland Parkinson’s Disease 
Society, all general practitioners, health workers, district nurses, and nursing homes 
in the study area. Some subjects within the study area, for example those with very 
early and undiagnosed disease, may still have been missed, as indicated by generally 
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higher prevalence rates of PD in door-to-door surveys.17 We are, however, convinced 
that our approach of patient selection was the best possible and available for our 
purpose, and that near all patients within the study area suffering from PD at 
prevalence day on January 1st, 1993, were included. Of note, due to a stable patient 
population and only few patients withdrawing their consent in participation, loss to 
follow-up for these reasons was very low. However, a concern in our study design 
was the rather long time intervals between study visits, resulting in a high attrition 
rate and potentially confounding due to death. 
Another important issue in epidemiological research is the use of appropriate 
measurement instruments. We performed standardized assessment of our patients at 
each study visit and applied generally accepted and validated measurement 
instruments. These are thoroughly described in the first and third part of this thesis. 
However, because of lack of validated tools for assessment of some non-motor 
features in PD at study start, self-constructed questionnaires or combined information 
from different scales had to be used to assess the frequency and severity of some of 
these symptoms. We attempted to solve this problem of uncertain validity by 
including later developed and validated measurement instruments and by comparing 
their results with those derived from our self-constructed tools, as it was done for FSS 
and ESS. The fact that our classifications of fatigue and EDS correlated with these 
widely used and acknowledged assessment tools therefore was an important 
observation and strengthened our findings on these features. Adding the FSS and ESS 
was undoubtedly also helpful to make our results better comparable with those of 
later published studies on fatigue and EDS in patients with PD. 
Last but not least, the application of adequate statistical methods is an important 
methodological aspect. However, particularly longitudinal studies using multiple 
observations over time may be a challenge to the researcher and statistician, as usual 
statistical techniques for analysis of longitudinal data are not applicable. In study 1, 
we measured disease progression by comparing mean changes in severity of 
symptoms from baseline to the first and second follow-up visit in smokers and non-
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smokers, thus following a statistical approach similar to those chosen in several 
clinical PD trials.208, 246 In study 2 to 4, we used logistic regression models for 
correlated data. These account for multipe visits per individual and the fact that 
characteristics of a single subject over time are likely to correlate with each other.239 
They allow quantifying the difference in scores at each study visit between patients 
who have a given factor at baseline versus those who have not. Logistic regression 
for correlated data accounts for missing data and allows including categorical and 
continuous variables in one model. 
5.2 Risk factors and the rate of disease progression in PD 
The role of genetic and environmental factors in the pathogenesis of PD has been the 
focus of research and debate over several decades. Since the first reports on the 
inverse relationship between smoking and PD were published almost fifty years ago, 
numerous studies have suggested a biological protection by cigarette smoking against 
nigral neuronal degeneration. In a recent systematic review of prospective studies, the 
pooled risk estimate between ever smokers and PD was about 0.5, meaning that those 
ever having smoked are half as likely to develop PD compared to never-smokers.247 
Surprisingly, during the same period only one study, following 30 patients over 3 
years, investigated the influence of cigarette smoking on disease progression in PD 
and found no difference between smokers and non-smokers. As we hypothesized that 
cigarette smoking, if significantly neuroprotective, would slow down functional 
decline in patients already diagnosed with PD, we measured in study 1 changes in 
severity of parkinsonism, disability, cognitive impairment and mood over an eight 
year period in smoking and non-smoking patients with the disease. We also compared 
the prevalence rate of smokers among PD patients and control groups with similar 
age and sex distribution. In these groups consisting of healthy elderly and patients 
with diabetes mellitus, we found a 50% higher prevalence of smokers than in patients 
with PD, which is in line with previous studies.247 This was an important finding as it 
indicated that smoking habits in our PD population were in principal not different 
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from those of previously investigated cohorts. However, progression of motor 
impairment, disability, mood, and cognitive impairment was not different in smokers 
and non-smokers. Of importance, this finding was not confounded or biased by 
selective mortality in the group of smoking patients as has been suggested previously 
to potentially explain the inverse relationship between smoking and PD.248 
What may explain our findings of a lower prevalence of smokers in PD, but similar 
disease progression in nonsmoking and smoking patients with the disease? 
We can not exclude that we have failed to detect less rapid disease progression in 
smoking patients due to methodological weaknesses in our study design. The rather 
small sample sizes at the last follow-up visit limited the statistical power, and thus 
differences in progression between the groups may have been missed. Therefore, we 
regarded the change in clinical features during the first four years of follow-up as the 
primary outcome. Also the fact that smoking habits were not updated at follow-up 
may have biased our results. Although we are unaware of any non-smokers starting 
smoking during follow-up, some patients may have quit smoking during the study 
period. We neither considered the possible influence of other substances such as 
coffee and alcohol on disease progression. However, based on the assumption that 
these are related to cigarette smoking and are suggested to have synergistic effects in 
protecting against nigrostriatal damage, one would expect a more pronounced rather 
than less difference in disease progression. Nevertheless, incorporation of these data 
would unlikely have changed our results substantially, as changes in severity of all 
assessed features were highly insignificant during both the first four and the entire 
eight years of follow-up. In a comment on our paper, Papapetropoulos and coworkers 
confirmed our findings and reported no difference in clinical characteristics of 
smokers, nonsmokers and past smokers in 127 deceased patients with pathologically 
confirmed diagnosis of PD, except for age at death. These results and their 
observation of younger age at disease onset in smokers than nonsmokers are in 
agreement with our and other52, 249 findings and seem to contradict that cigarette 
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smoking, as a single factor, has clinically significant neuroprotective effect in patients 
already diagnosed with PD. 
Interestingly, in several studies,52, 250, 251 but not all,252 the inverse relationship 
between smoking and PD was present only or most pronounced in patients with early 
onset of PD in which genetic factors are more likely to be involved in the 
pathogenesis of the disease. In line with this, results from a recent well-designed 
Swedish case-control study using both co-twin and unrelated controls indicate that 
the association between smoking and PD to some extent is due to familial or genetic 
confounding.253 Interactions between cigarette smoking and genes involved in 
familial PD, oxidative stress, and detoxification of metabolites have been suggested 
to modify the relationship between smoking and PD,53-55 but could not be confirmed 
in larger studies or remain to be replicated.254 
Another possible explanation is that patients with PD may be less prone to start 
smoking, and thus failure to develop strong smoking habits may be the first 
manifestation of the disease. Also, patients with PD may be more likely to quit 
smoking before clinical disease onset. In a recently published study investigating the 
relationship between life-style risk factors and personality traits in PD, patients 
stopped smoking in average 16.2 years prior to the onset of motor symptoms.255 In 
this sense, the causation between smoking and PD would be reversed, and PD would 
„protect against smoking“.256 A premorbid parkinsonian personality trait has been 
suggested in several studies.49 Patients with PD are described as passiv, self-
controlled, introverted, and less likely to take risks. Studies indicate that PD patients 
score lower than controls on a personality trait called novelty seeking which is 
hypothesized to be dopamine driven.51 Dopamine is likely to play an important role 
in pleasure and reward systems, as also indicated by reports of levodopa addiction 
and personality changes in PD patients with dopamine dysregulation syndrome.257 
Moreover, a recent study found that low sensation seeking independently predicts PD 
after adjusting for smoking, caffeine and alcohol intake.255 However, in a nested case-
control study, the inverse association between smoking and PD was present even in 
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PD patients with the highest scores for depression and social introversion, assessed 
decades before clinical onset.258 The latter observation would argue against a reverse 
causation hypothesis, but has still not been published in detail and should therefore be 
interpreted with caution. Identification and prospective neuropsychological studies of 
subjects with preclinal PD seem now to be within reach and would be able to provide 
valuable information whether and to which extent a premorbid parkinsonian 
personality traits could explain the comparatively low prevalence of smokers among 
PD patients. 
In a more comprehensive survey (study 3), we prospectively assessed potential 
demographic and clinical risk factors and the rate of functional decline in our PD 
cohort. Although a number of studies had investigated predictors of disease 
progression in PD prior to our study, most of them were potentially biased by 
methodological weaknesses, including short follow-up, small sample size, selected 
patient cohorts and retrospective design. Not surprisingly, their results were 
contradictory on many potential risk factors and varying regarding the rate of disease 
progression.122 
Because predictors and the rate of functional decline may vary depending on what 
kind of assessment tool is used, we decided to measure the progression of motor 
impairment and disability each independently by two different assessment tools, all of 
whom are widely used and acknowledged by PD researchers. Our observation of 
similar annual changes in severity of motor symptoms and disability in between 3.1% 
and 3.6% measured by four different measurement instruments was valuable not only 
from a clinicometric point of view. They also indicated that the rate of motor 
progression, as derived by long-term follow-up of an unselected patient cohort, is at 
least twice as high as reported previously from other prospective longitudinal 
investigations.116 Interestingly, Louis and colleagues investigated motor progression 
in a population-based cohort with almost identical sample size, gender distribution, 
age at onset, and age at baseline, but with shorter disease duration and follow-up 
compared to our study, and found only a 1.5% annual decline in UPDRS motor 
  70 
score.116 Jankovic et al. reported a 0.7% motor progression in their study with similar 
follow-up compared to our, but using a selected cohort of patients with rather young 
age at onset.117 These differences in progression rates and the fact that both studies 
failed to identify independent risk factors of motor decline illustrate that rather small 
methodological varieties in longitudinal studies in PD may have major impact on 
their outcome. 
An important part of this study was to explore the relative importance of different 
baseline variables for future functional decline. We therefore conducted logistic 
regression analysis for correlated data and included a wide range of clinical and 
demographic features as independent variables. By testing each independent variable 
for interaction with follow-up time it is possible to judge whether this variable is 
associated with more rapid progression of the dependent variable. From an etiological 
point of view it was of interest to explore the importance of both the patients’ age at 
onset and their age at baseline in addition to disease duration, because they are likely 
to reflect different pathogenic mechanisms. As these variables could not be assessed 
in one model due to collinearity, we performed two analyses in which age at onset 
and disease duration were included in the main model, and age at onset and age at 
baseline in a supplemental analysis. 
We found that the presence of non-motor symptoms thought to be due to non-
dopaminergic pathology, such as cognitive impairment and EDS, predicts a poor 
outcome in the sense of more impaired motor function and disability. We believe that 
these conditions in general reflect more advanced and widespread disease, in which 
also typical motor symptoms become less responsive to dopaminergic stimulation, 
possibly due to degeneration in postsynaptic dopaminergic terminals. Also a higher 
age at baseline and longer disease duration predicted higher levels of functional 
impairment during follow-up, but none of these features did interact significant with 
time. Thus, we could not confirm the results from a recent neuroimaging study 
suggesting that the rate of progression may decrease in a negative exponential 
manner.72 In fact, we consider this to be one of the major findings of our study, as it 
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highlighted the current limitations of neuroimaging studies to reflect clinical long-
term disease progression in PD by measuring dopamine transporter activity or 
metabolism. 
We found time interactions only for the patient’s age at onset, however, both for the 
UPDRS motor scale and the Hoehn and Yahr staging, which clearly strengthens the 
significance of this finding. Advanced age at onset but not higher age per se therefore 
appears to be the major predictor of motor decline in PD, as indicated by previous 
studies, suggesting that PD is not due to an accelerated aging process.102, 120 For 
example, we estimated the rate of motor decline measured by the UPDRS motor scale 
to be about 1.5 more rapid in patients with disease onset at 70 years compared to 
those with onset at an age of 50 years, and almost twice as rapid using the Hoehn and 
Yahr staging. Our statistical method also allowed to estimate the time for progressing 
one Hoehn and Yahr stage, which was 5.1 year for patients with disease onset at 70 
years and 9.3 years for those who were diagnosed with PD at an age of 50 years. To 
our knowledge, we were the first to present age at onset-dependent estimates on 
progression rates derived from long-term follow of a representative PD cohort. It is, 
however, important to note that our estimates were derived from drug-treated patients 
in their on-stage, and that the natural progression of the disease is likely to be more 
rapid, at least in patients with early disease. In contrast, our results provide more true-
to-life estimates on functional decline and may be particularly relevant for long-term 
investigations of symptomatic or potentially neuroprotective agents in PD. 
 
5.3 Fatigue within the non-motor symptom complex of PD 
Although fatigue is one of the most frequent and disabling non-motor features in PD, 
described as their most disabling symptom by one-third of patients with the disease, it 
is under-recognised by clinicians as well as researchers. Basically, fatigue is a highly 
physiological phenomen, describing tiredness, weariness, exhaustion or drain of 
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energy, and a normal feedback of perceived exertion. However, in research terms it is 
best understood as a pathologically amplified reaction to mental or physical tasks. A 
now widely accepted and used definition of fatigue is ”an overwhelming sense of 
tiredness, lack of energy, or feeling of exhaustion”.259 
Fatigue is not specific to any disorder in the sense that it is common in several 
neurologic, psychiatric, and systemic diseases.143, 260, 261 Suggested underlying 
pathways depend on the type of disorders, and include abnormal immune response, 
alterations in neurotransmitter signaling, and genetic predisposition, among others. 
Our study (study 2) was the first to investigate fatigue prospectively over time in a 
community-based cohort of PD and was primarily motivated by a previous report of 
persistence of fatigue in a small sample of retrospectively assessed patients with 
PD.156 In addition, we aimed to clarify to which extent the relationship to other motor 
and non-motor features could explain the prevalence of fatigue, as previous 
prevalence studies had shown inconsistent results.145 In general, persistence and 
increase of prevalence over time indicate a symptom to be caused by structural 
lesions rather than due to counfounding by comorbidity or overlap with other 
features. 
Methodological challenges in assessing fatigue in PD include the lack of objective 
measurement instruments, the overlap of symptomatology with other non-motor 
problems, and the fact that it is not specific to the disease. In addition, fatigue may 
have different dimensions, and we therefore specified that we aimed to investigate 
aspects of mental fatigue. Because it is highly subjective, the most appropriate way to 
assess fatigue is to measure the patient’s own perception of this complaint by self-
report. We used combined information from a seven-point fatigue rating scale and 
from parts of the energy-dimension in the Nottingham Health Profile to measure 
fatigue and extended our evaluation program in 2001 by the FSS which meanwhile 
had become an acknowledged and widely used assessment tool. However, although 
these assessment tools were designed to measure fatigue, none of them are specific to 
this complaint. To address the known problem of potential overlap and comorbidity 
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between fatigue and other PD features, we did a comprehensive assessment of other 
non-motor features and carried out multivariate analysis to identify covariates that 
were significantly related to fatigue. We then calculated prevalence rates of fatigue at 
each study visit for two different populations: first, for all included patients; and 
second, for a subgroup of patients defined by low levels of covariates associated with 
fatigue. 
Our results confirmed previous findings of a high frequency of fatigue in PD, 
affecting slightly less than 40% at baseline and more than 56% after eight years of 
follow-up. We further found that fatigue was related to other non-motor symptoms 
like EDS and depression, both of which are thought to origin from pathological 
changes outside the classical pathway of substantia nigra. Unfortunately, because of 
low specificy of current evaluation instruments, it remains unclear whether this 
association is causal or due to overlap of symptomatology. However, several 
observations in our study imply that fatigue cannot be explained by comorbidity 
alone: First, fatigue occurred as a frequent complaint also in patients without these 
symptoms; second, it increased in prevalence during follow-up; and third, fatigue was 
independently associated with the Hoehn and Yahr staging. Taken together, these 
findings strongly suggest that fatigue is caused by disease-related changes in a 
substantial part of patients with PD. 
Another aim of this study was to clarify whether fatigue is a persistent feature in 
patients with PD. We did not expect strict persistence of fatigue in our patients, again 
because of its in general multifactorial etiology and due to potential overlap and 
comorbidity with other symptoms in PD. In line with our expectations, but in contrast 
to the study by Friedman et al., fatigue occurred as a non-persistent symptom in 
almost half of those patients who participated in all study examinations. Our results 
therefore demonstrate that the symptomatology of fatigue in PD and its underlying 
causes are likely to be heterogeneous, and they also highlight the complex 
interactions between different non-motor symptoms in PD. In about half of the 
patients fatigue seems to be related to the disease pathology itself, and in the other 
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patients it may be explained by comorbidity or overlap with other non-motor 
problems, particularly depressive symptoms and EDS. This clearly contrasts the 
conclusion of a recently published review article, describing fatigue as a symptom 
that is unrelated to motor severity and sleep disturbances in patients with PD.145 
Our results have implications for clinical practice and future research on fatigue in 
PD: First, because fatigue is a frequent and increasing complaint it should be assessed 
regularly in routine examination of patients with PD. Second, in those suffering from 
fatigue, a thorough examination of other motor and non-motor symptoms should be 
conducted in parallel to elucidate if fatigue may be explained by these. If a 
relationship to other symptoms is likely and these are treatable, their treatment also 
may diminish the patient’s experience of fatigue. Third, future studies on fatigue 
should take into account the heterogeneity of fatigue in PD. For example, to obtain 
valid results in clinicobiological correlation studies, case ascertainment should 
preferentially concentrate on patients without overlapping symptomatology, as 
disease-related changes are most likely to explain fatigue in these subjects. 
5.4 Changes in motor subtype and risk for incident 
dementia in PD 
It is now established that cognitive impairment and dementia are common features in 
PD, developing in the vast majority of patients and predicting nursing home 
placement and mortality.134, 136, 173 Thus, cognitive decline in PD has major 
consequences for the patients themselves, their caregivers, and the health care system. 
It is therefore important to clarify which factors may predict future development of 
dementia. In addition, establishing associations between different symptom 
complexes within PD may contribute to increase our understanding of underlying 
pathological changes. 
The existence of clinical subtypes in PD has been suggested for several decades, 
based on differences in patterns of motor symptoms and their influence on cognitive 
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and functional decline. Later on, results from cerebrospinal fluid analysis in PD 
supported the concept of different motor subtypes in PD.262 Zetusky et al. were 
among the first to distinguish between a tremor-dominant (TD) subtype and motor 
impairment characterized by postural instability and gait difficulties (PIGD), and 
pointed out that TD parkinsonism is associated with relative preservation of mental 
functioning.263 In contrast, motor impairment characterized by postural instability and 
gait difficulties (PIGD) correlated with cognitive impairment in cross-sectional 
studies and predicted dementia in the only longitudinal investigation published prior 
to our study.141 Because both conditions are more or less refractory to dopaminergic 
treatment, underlying non-dopaminergic pathology has been suggested.264 
However, several issues regarding the relationship between these symptoms remained 
unclear or were not addressed in previous studies. For example, based on our clinical 
experience, we expected the motor subtypes to change over time, at least in some of 
our patients. This was important to consider in our study design (study 4). We also 
wondered whether eventual changes in predominant motor symptoms were associated 
with increased risk for becoming demented. Therefore, instead of assessing risk 
factors at baseline, we investigated how changes in motor subtypes during the study 
period influenced the development of both cognitive impairment and dementia in the 
subgroup of all 171 patients who were non-demented at baseline. This approach was 
also suitable to test clinically the proposal of a sequential development of disease 
pathology in PD as supposed by Braak et al.75, 76 Their hypothesis was met with 
scepticism when published in 2003, because it was based on cross-sectional data and 
suggested rather unexpectedly that the disease process begins in lower brainstem 
areas (vagus and olfactory nerve), remaining subclinical until substantia nigra is 
affected. While several clinical studies, particularly those investigating olfactory 
function, have provided clinical support to a stagewise progression of PD pathology 
in subclinical and early PD,202 we were unaware of any studies supporting Braak’s 
proposal in advanced disease. Based on the assumption that brainstem and midbrain 
locomotor areas (Braak stage 3 and 4) are crucial for control of balance and gait, 
  76 
while cortical deficits (stage 5 and 6) best relate to dementia in PD, one would expect 
a sequential development of these symptoms in patients with PD. 
We found that a considerable portion of our patients changed their motor subtype 
during the eight years of follow-up. In this context, an important observation was that 
these changes in motor subtype were not random, but clearly unidirectional from 
early TD parkinsonism via the indeterminate to the PIGD motor subtype. This finding 
confirmed the proposal that motor subtypes may differentiate or evolve during the 
course of the disease, as suggested previously based on cross-sectional data and CSF 
analysis in patients with PD.102, 262 Compared to 54% at baseline, 88% of our patients 
had developed clinically significant and irreversible postural instability and gait 
problems at study end, despite dopaminergic treatment, which implies underlying 
cerebral changes involving non-dopaminergic pathology. This is identical to the 88 % 
prevalence of PIGD motor subtype in patients with PDD reported previously.264 
Our data further suggest that a minority of patients remains with a tremor-dominant 
disease pattern, and that these patients are “protected” against cognitive decline and 
development of dementia. Patients with persistent TD parkinsonism showed a total 
MMSE decline of only 1.2 points during eight years, compared to an expected 
decline in MMSE of one point per year in the general PD population.132 One could 
argue that these patients may not suffer from PD but another disease, for example 
essential tremor which is frequently misdiagnosed as PD and associated with 
preserved cognitive function. However, although we have no confirmation of the 
clinical diagnosis by autopsy in these patients, they all fulfilled criteria of PD at each 
study visit, presenting at least one additional cardinal feature in addition to resting 
tremor and most of them a asymmetric disease pattern. Interestingly, a very recent 
study supports these finding and suggests the existence of a subgroup of patients with 
PD suffering from “benign tremulous parkinsonism".265 The clinical features and 
longitudinal course in these patients, including preserved cognitive function and 
rather poor levodopa responsiveness of tremor, were strikingly similar to those 
observed in our patients with persistent TD subtype. Neuroimaging studies in patients 
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with this phenotype further demonstrate reduced striatal dopaminergic uptake, as 
expected in PD but not in tremor syndromes.266 We speculated that disease pathology 
in patients with persistent TD parkinsonism may progress differently and for some 
reason remains more restricted than in patients developing indeterminate or PIGD 
motor subtype. 
Somewhat unexpectedly, we observed a strict sequential development of PIGD motor 
subtype and dementia in our cohort in the sense that, except for one, no patient was 
diagnosed with dementia before transition to PIGD parkinsonism. It was therefore not 
surprising that we found very high odds ratios for dementia for those who had or 
developed PIGD subtype compared to patients with stable TD or indeterminate motor 
subtype. However, the intervals between study visits were rather long, and some 
patients with TD or indeterminate subtype might have been found to be demented 
using more frequent study visits. In a previously published prevalence study, 5% of 
demented patients presented with TD parkinsonism.264 We therefore also investigated 
the relationship between motor subtype and dementia diagnosis in the primarily 
excluded patients with dementia at baseline and found again that all but one of these 
suffered from clinically significant gait and balance problems. This observation 
clearly strengthened our primary findings in non-demented PD patients. 
An important step to further clarify the relationship between PIGD and cognitive 
decline was to additionally investigate the rate of MMSE decline before and after 
changes in subtype of parkinsonism, because the MMSE score is a more sensitive 
method to detect minor or beginning cognitive impairment and thus better reflects the 
slowly progressive cognitive decline in patients with PD. Our finding of a more than 
threefold accelerated rate of MMSE-decline in those evolving from TD to PIGD 
parkinsonism strongly suggests that the cognitive decline in patients with PD starts in 
parallel to the development of clinically significant gait and balance problems. This 
also explains our observation of a subsequent diagnosis of dementia.  
At the time of submission of our study there was convincing evidence for an 
involvement of the pedunculopontine nucleus (PPN) in controll of postural instability 
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and gait problems, however, based on results from animal studies only.109 Very 
recently, two independent preliminary investigations reported marked improvement 
of akinesia and postural instability by deep brain stimulation (DBS) of the PPN in 
patients with PD.267, 268 It is therefore reasonable to relate the development of PIGD 
motor subtype in our cohort to functional or structural changes in the PPN or vicinal 
brainstem nuclei. Our findings on the strong temporal relationship between 
development of gait and balance problems on one hand and cognitive impairment on 
the other thus suggest that brainstem pathology is involved in the pathogenesis of 
(early) cognitive impairment in PD. Previous and more recent neuropathological 
studies, among these an autopsy study in a subgroup of our own cohort, support this 
assumption.76, 242 In addition, our results may indicate that Braak’s proposal of a 
sequential development of PD pathology is true also in advanced disease. However, 
whether and to which extent the PPN is directly or indirectly involved in the etiology 
of cognitve decline in PD remains unclear. Our study group plans to further 
investigate this issue in clinicopathological correlation studies of patients derived 
from our own cohort. 
Finally, our findings suggest that the frequency and extent of cognitive assessments 
in patients with PD may be adjusted to their expected risk to become demented. 
Because patients developing clinically significant gait and balance problems are at 
50% risk for dementia within the following four years, more frequent clinical follow-
up in these subjects may lead to early detection and treatment of their cognitive 
deficits.  
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6 Conclusions 
The aims of this thesis were to describe and achieve a better understanding of aspects 
related to the clinical disease progression in Parkinson’s disease (PD). All studies 
were conducted in a population-based cohort of patients with PD followed 
prospectively over an eight-year period. 
The etiology and relative importance of genetic and environmental factors for the 
development and progression of PD are widely unknown. Lifestyle factors including 
cigarette smoking have been suggested to modify the course of the disease. In an 
exploratory study, we therefore investigated the relationship between cigarette 
smoking and PD. We confirmed previous findings of an inverse relationship between 
smoking and prevalent PD, but found no differences in progression of parkinsonism, 
disability, mood, and cognitive impairment during eight years of follow-up. Our 
results may indicate that smoking, as a single factor, does not have major 
neuroprotective effect in patients already diagnosed with PD. 
In a more comprehensive study investigating clinical and demographic risk factors 
and the rate of functional decline, we show that motor symptoms and disability in PD 
progress with similar annual rates of 3.1% to 3.6%. This is in line with the general 
understanding of PD as a slowly progressive neurodegenerative disorder. However, 
the rate of functional decline varies between subgroups. Our data suggest that 
advanced age at onset is the major predictor of more rapid motor progression in 
patients with PD. 
We further investigated different aspects of disease progression within the non-motor 
symptom complex of PD. We found that fatigue is a frequent and increasing 
complaint in PD. In about half of the patients it occurs as a fluctuating symptom and 
is related to other non-motor symptoms like depression and excessive daytime 
somnolence. However, fatigue appears independently from these symptoms in a 
substantial part of patients with PD and behaves like a symptom caused by 
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malfunction or damage of relevant but so far unidentified brain areas. 
Finally, we demonstrated that development of clinically significant postural 
instability and gait problems in PD is associated with a more than threefold 
accelerated cognitive decline and a 50% risk for becoming demented within the 
following four years. Our findings suggest common or parallel underlying 
pathological changes of gait and balance problems and cognitive impairment, and 
they also lend clinical support to Braak’s hypothesis of a sequential development of 
pathological changes in PD. 
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